


Article

# A TLR/CD44 axis regulates T cell trafficking in experimental and human multiple sclerosis



Maria Tredicine,  
Chiara  
Camponeschi,  
Davide Pirolli, ...,  
Gabriela  
Constantin,  
Francesco Ria,  
Gabriele Di Sante

francesco.ria@unicatt.it (F.R.)  
gabriele.disante@unipg.it  
(G.D.S.)

Highlights

Environment and genetic  
are both involved in the  
regulation of T cell motility

Pathogens and  
commensals impact on T  
cell trafficking through a  
TLRs/CD44v axis

Regulation of CD44  
isoforms by TLRs is a new  
pathogenetic mechanism  
of autoimmunity

Modulation of CD44  
isoform can be a new  
target for therapy of  
multiple sclerosis

Tredicine et al., iScience 25,  
103763  
February 18, 2022 © 2022 The  
Authors.  
[https://doi.org/10.1016/  
j.isci.2022.103763](https://doi.org/10.1016/j.isci.2022.103763)



## Article

A TLR/CD44 axis regulates  
T cell trafficking in experimental  
and human multiple sclerosis

Maria Tredicine,<sup>1</sup> Chiara Camponeschi,<sup>1</sup> Davide Pirolli,<sup>2</sup> Matteo Lucchini,<sup>3,4</sup> Mariagrazia Valentini,<sup>3</sup> Maria Concetta Geloso,<sup>3,5</sup> Massimiliano Mirabella,<sup>3,4</sup> Marco Fidaleo,<sup>6</sup> Benedetta Righino,<sup>2</sup> Camilla Moliterni,<sup>6</sup> Ezio Giorda,<sup>7</sup> Mario Rende,<sup>8</sup> Maria Cristina De Rosa,<sup>2</sup> Maria Foti,<sup>9</sup> Gabriela Constantin,<sup>10</sup> Francesco Ria,<sup>1,3,11,\*</sup> and Gabriele Di Sante<sup>1,8,11,12,\*</sup>

## SUMMARY

**In the pathogenesis of autoimmune disorders, the modulation of leukocytes' trafficking plays a central role, still poorly understood. Here, we focused on the effect of TLR2 ligands in trafficking of T helper cells through reshuffling of CD44 isoforms repertoire. Concurrently, strain background and TLR2 haplotype affected Wnt/ $\beta$ -catenin signaling pathway and expression of splicing factors. During EAE, mCD44<sub>v9-v10</sub> was specifically enriched in the forebrain and showed an increased ability to bind stably to osteopontin. Similarly, we observed that hCD44<sub>v7</sub> was highly enriched in cells of cerebrospinal fluid from MS patients with active lesions. Moreover, TLRs engagement modulated the composition of CD44 variants also in human T helper cells, supporting the hypothesis that pathogens or commensals, through TLRs, in turn modulate the repertoire of CD44 isoforms, thereby controlling the distribution of lesions in the CNS. The interference with this mechanism(s) represents a potential tool for prevention and treatment of autoimmune relapses and exacerbations.**

## INTRODUCTION

T cell trafficking is a central and highly regulated process during the immune response. Chemokines, chemokine receptors, integrins, selectins, matrix-associated proteins, and related receptors, all play a specific role in the coordinated process of guiding specific subsets of T cells to the most appropriate site for action (Oukka and Bettelli, 2018; Sandor et al., 2019; Strazza et al., 2015). Interfering with this process currently represents an attractive and efficient tool for therapeutic intervention in autoimmune diseases by preventing relapses and exacerbations (Calvier et al., 2020; Mousavi, 2020). Among autoimmune disorders, understanding disease pathogenesis in multiple sclerosis (MS) is challenging, because the distribution of lesions within the CNS is difficult to predict. Several factors have been called to play a role including antigen (Ag) density, T cell phenotype, and local milieu at the site of infiltration (Gross et al., 2017; Lindner et al., 2018).

We previously reported that pathogen recognition receptors (PRR) have a role in the control of lymphocytes' trafficking. Mobilization of activated Ag-specific T cells critically depends on the amount of the stimuli from the environment in combination with the genetic background. Indeed, we demonstrated that the amount of *Mycobacterium tuberculosis* (*Mtb*) in the adjuvant (Nicolò et al., 2013) impacts immune cells trafficking in different mouse strains, based on a polymorphic residue at position 82 of mouse TLR2 (82Ile in SJL/J versus 82Met in C57Bl/6 mice): high concentrations of *Mtb* in the adjuvant are needed for early mobilization of activated T cells in the SJL/J strain, while challenge of C57Bl/6 leads to early mobilization independently of the amount of *Mtb* (Nicolò et al., 2013; Piermattei et al., 2016). In addition, we observed that pathogens were able to directly regulate T cell trafficking by binding TLR2 expressed by T cells following Ag-driven activation (Piermattei et al., 2016), whereas their ability to modulate the Th phenotype of activated T cells relies on indirect activation through TLR2 expressed by APCs (Fallarino et al., 2016; Luz et al., 2015).

<sup>1</sup>Department of Translational Medicine and Surgery, Section of General Pathology, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy

<sup>2</sup>Institute of Chemical Sciences and Technologies "Giulio Natta" (SCITEC) -CNR, Largo Francesco Vito 1, 00168 Rome, Italy

<sup>3</sup>Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli 1-8, 00168 Rome, Italy

<sup>4</sup>Centro di ricerca per la Sclerosi Multipla (CERSM), Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy

<sup>5</sup>Department of Neuroscience, Section of Human Anatomy, Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168 Rome, Italy

<sup>6</sup>Department of Biology and Biotechnology Charles Darwin, University of Rome Sapienza, 00185 Rome, Italy

<sup>7</sup>Core Facilities di Ricerca, Ospedale Pediatrico Bambino Gesù Roma – IRCCS, V.le Ferdinando Baldelli, 40, 00146 Roma, Italy

<sup>8</sup>Department of Medicine and Surgery, Section of Human, Clinic and Forensic Anatomy, University of Perugia, Piazza L. Severi, 06132 Perugia, Italy

<sup>9</sup>Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

<sup>10</sup>Department of Medicine, Section of General Pathology, University of Verona, Strada le Grazie 8, 37134 Verona, Italy

<sup>11</sup>Senior authors

Continued



Interestingly, we also observed that TLR2 polymorphic residue at position 82 also associated with differences in the distribution of CNS lesions during experimental autoimmune encephalomyelitis (EAE) (Piermattei et al., 2016), suggesting a more complex role for TLR2 in regulating T cell trafficking.

CD44 represents one of the best markers for bone marrow-derived cells infiltrating the CNS (Brennan et al., 1997; Fagone et al., 2018). It is expressed in several alternatively spliced isoforms, the most common of which, herewith CD44s (standard), is the shortest one, lacking all variant exons and accounting for most of the repertoire of mRNAs specific for CD44. All CD44 isoforms share trans-membrane, intracytoplasmic, and ligand-binding (NH-terminal) domains. The closest region to the membrane of the extracellular domain is the most variable and is involved in the regulation of cell–cell and cell–matrix interactions, homing, lymphopoiesis, and cell activation (Di Sante et al., 2013). Some of these functions are linked to the ability of CD44 to bind to the hyaluronic acid (HA) (Galluzzo et al., 1995). Moreover, it has been previously described a specific role of CD44 isoforms in the pathogenesis of immunomodulated diseases (Di Sante et al., 2013), whereas involvement of CD44v5 was shown in the pathogenesis of asthma (Yang et al., 2012). In addition, CD44<sub>v3/v6</sub> was proposed as biomarker of disease activity in systemic lupus erythematosus (SLE) (Latini et al., 2021; Novelli et al., 2019). Decrease of CD44 expression leads to a reduction of adhesive interactions with lymph node matrix, thereby facilitating the exit of T cells from lymph nodes (Brennan et al., 1997; McDonald and Kubes, 2015). However, it is not clear the role that the different isoforms play in the regulation of cell trafficking, nor which stimuli modify the composition of the CD44 repertoire in T cells. The role of CD44 isoforms on activated T cells was explored during chronic-relapsing EAE, and the results showed that anti-CD44 antibodies inhibit the migratory capacity of T cells (Brennan et al., 1999), whereas the ablation of exons v7 and v10 significantly reduced EAE severity (Ghazi-Visser et al., 2013).

In this work, we examined the role of TLR2 in the regulation of trafficking of T cells, focusing on its ability to reshuffle the role of CD44 and the alternative splicing of its pre-mRNA. In addition, we also showed that stimulation of T cells by LPS or CpG (activating other TLRs also expressed by T cells) modified the alternative splicing of CD44, leading to a repertoire of CD44 isoforms-specific mRNAs that varied specifically depending on the type of stimulus. Notably, T cells infiltrating distinct areas of the CNS during EAE displayed different levels of mRNAs coding for specific CD44 isoforms. Finally, we report that overexpression of an isoform of CD44 in cells of the cerebrospinal fluid (CSF) was associated with presence of active inflammatory lesions in human multiple sclerosis (MS).

## RESULTS

### ***Mtb*- and TLR2-dependent, early mobilization of PLP<sub>139-151</sub>-specific, activated T cells associated with lower surface expression of CD44**

We first examined the molecular mechanisms translating TLR2 stimulation into regulation of T cell trafficking from the lymph nodes (LN), and performed microarray analysis, comparing mRNA from T cells obtained from the LN of SJL/J mice challenged with adjuvant containing 50 versus 200 µg/20g of heat-inactivated *Mtb* (Figure 1A). We also compared the results with those obtained from challenging F1 mice of SJL/J<sup>wt</sup>xC57Bl/6<sup>wt</sup> and SJL/J<sup>wt</sup>xC57Bl/6<sup>tlr2<sup>-/-</sup></sup> that were previously described (Figure 1F), thus reproducing the conditions of the experiments reported in (Piermattei et al., 2016). However, the analysis of the results did not show a parallel regulation of mobility for any of the proteins most obviously linked to T cell mobility (e.g., CD49d, CD11a, S1P-R and CD62L, chemokines, or chemokine receptors). Indeed, we therefore proceeded to examine the expression of these markers known to play a relevant role in the interaction between leukocytes and endothelia on antigen-specific activated T cells (Figures 1B–1D and 1G–1I).


To study the level of expression of these adhesion molecules, we took advantage of a mouse SJL/J strain transgenic for the β-chain of a PLP<sub>139-151</sub>-specific TCR (vβ10, SJL/J<sup>vβ10+</sup>) (Nicolò et al., 2006, 2013), that is not spontaneously activated *in vivo*, but upon immunization (Penitente et al., 2008). The staining of lymph nodes-derived vβ10<sup>+</sup>CFSE<sup>low</sup>T cells with CD49d, CD11a (LFA-1), and CD62L, revealed no differences of expression in conditions leading to fast or low mobilization (Figures 1B–1D), while a decrease (approximately, 5-fold) of the expression of CD44 was observed when cells from fast mobilizer condition were examined (Figure 1E).

The levels of these cell surface markers were more variable between F1 (SJL/J<sup>vβ10+</sup>xC57Bl/6<sup>wt</sup>) and F1 (SJL/J<sup>vβ10+</sup>xC57Bl/6<sup>tlr2<sup>-/-</sup></sup>), probably due to interferences between the different genetic backgrounds (Figures 1G–1I). However, again we found that F1 (SJL/J<sup>vβ10+</sup>xC57Bl/6<sup>wt</sup>), the fast mobilizer genetic background,

<sup>12</sup>Lead contact

\*Correspondence:  
francesco.ria@unicatt.it (F.R.),  
gabriele.disante@unipg.it  
(G.D.S.)

<https://doi.org/10.1016/j.isci.2022.103763>



**Figure 1. The amount of *Mtb* and TLR2 haplotype regulates surface expression of CD44 on antigen-specific proliferating T cells**

(A–J) The expression levels of CD49d (B and G), CD11a (LFA-1, C and H), CD62L (D and I), and CD44 (E and J), all APC conjugated on PLP<sub>139-151</sub>-specific (TCR-V $\beta$ 10<sup>+</sup>-PE) proliferating (CFSE-FITC<sup>low</sup>) T cells were evaluated by flow cytometry. (A and F) Gating strategies. (B–E) Two groups of four SJL/J<sup>V $\beta$ 10+</sup> mice were immunized with an emulsion of PLP<sub>139-151</sub> (PLP) in CFA containing two different concentrations of heat-killed *Mtb*: 200 ( $\mu$ g/mouse, fast mobilizer, blue) or 50  $\mu$ g/mouse (slow mobilizer, red). (G–J) Two groups of four F1 mice, SJL/J<sup>V $\beta$ 10+</sup> $\times$ C57Bl/6<sup>wt</sup> (fast mobilizer, blue) and SJL/J<sup>V $\beta$ 10+</sup> $\times$ C57Bl/6<sup>tlr2-</sup> (slow mobilizer, red) were challenged with PLP in CFA containing 50  $\mu$ g/mouse of *Mtb*. T cells from draining LN were labeled with CFSE-FITC and stimulated *in vitro* with PLP. Three days later, cells were recovered stained for v $\beta$ 10-PE and the expression of markers upon described was compared on V $\beta$ 10<sup>+</sup> CFSE<sup>low</sup> cells, i.e., T cells that had proliferated in response to PLP.

(K and L) CD4<sup>+</sup> CD62L<sup>low</sup> T cells were isolated from SJL/J (n = 15 mice, in three different experiments, K) and C57Bl/6 (n = 4, L) mice' spleens. T cells were plated on Matrigel® and stimulated with different conditions and in the presence (red bars) or absence (green bars) of  $\alpha$ -pan-CD44 mAb. After 24 h, cells that passed the Matrigel® were harvested and counted by flow cytometry. Data are expressed as percentage of cells recovered in the lower chamber. Statistical analysis was performed by two-way ANOVA, Tukey's multiple comparisons. Data are shown as mean  $\pm$  SD. Only significant p values are displayed.

associated with a lower expression of CD44 on the surface of activated T cells (Figure 1J), suggesting that conditions leading to fast or slow mobilization from lymph nodes of activated T cells associated with the expression of low or high levels of CD44 on T cells, respectively.

### Stimulation of activated CD4<sup>+</sup> T cells by TLR2 ligands reshuffled the role of CD44 in T cell trafficking

To better understand the effect of TLR2 ligation on trafficking properties of T cells due to CD44 regulation, we measured the ability of CD4<sup>+</sup>CD62L<sup>low</sup> T cells to cross Matrigel in a standard assay, upon cognate stimulation by biotinylated microparticles loaded with mouse  $\alpha$ CD3 and  $\alpha$ CD28 antibodies (Ab), in the

presence or absence of synthetic TLR2 ligands (a cocktail of Pam2/CSK4 and Pam3/CSK4) and of  $\alpha$ -panCD44 mAb, to assess its contribution to modification of trafficking.

As expected,  $\alpha$ -panCD44 mAb increased the number of unstimulated T cells crossing the Matrigel in both SJL/J and C57Bl/6 mice (Figures 1K and 1L). These observations confirmed the data reported in the literature showing that interaction of CD44 with extracellular matrix results in an inhibition of T cell mobility (Baaten et al., 2010; Govindaraju et al., 2019).

A simultaneous stimulation of TLR2/TLR6 (with Pam2/CSK4) and of TLR2/TLR1 (with Pam3/CSK4) heterodimers of SJL/J-derived T cells led to an increase of the number of cells crossing the Matrigel, confirming that stimulation through this pathway was efficient in promoting cell mobility. Unexpectedly, however, in these conditions, blocking CD44 resulted in a significant decrease in the number of T cells crossing the Matrigel, in the SJL/J strain (One-way ANOVA test,  $p = 0.01$  with PAM2/CSK4 and  $\alpha$ CD3/ $\alpha$ CD28, and  $p = 0.04$  with combined PAM3/CSK4 and  $\alpha$ CD3/ $\alpha$ CD28). The same result was observed when SJL/J T cells were stimulated by microparticles ( $\alpha$ CD3/ $\alpha$ CD28). Thus, upon stimulation by TLR2 ligands, CD44 reshuffled its functional properties and T cell trafficking through the Matrigel became CD44-dependent (Figure 1K). However, such a reshuffling of CD44 function did not occur in T cells from the C57Bl/6 strain (Figure 1L).

### Cognate stimulus and engagement of TLR2 modified the expression and function of CD44 and modulated alternative splicing of CD44 pre-mRNA

As mentioned above, CD44 comprises several isoforms, differing in their sequences due to alternative splicing of exons. mRNA coding for the shortest isoform represented the most easily detected product of alternative splicing of CD44 pre-mRNA. As expected, mRNA specific for the shortest isoform (CD44s) was the most represented in unstimulated T cells (Figure S1).


The activation of T cells via CD3/CD28 led to an increase of CD44s mRNA (Figures 2A and 2B). Likewise, triggering of TLR2 (but also of TLR9 and TLR4) led to an increase of mRNA specific for CD44s. However, we consistently observed that simultaneous triggering of both CD3/CD28 and TLR2/TLR6 dimer (Figure 2C) reduced the mRNA specific for this isoform. This observation suggests that cognate interaction leads to a decrease of CD44s to license activated T cells to exit LN, only when a concomitant signal through TLR-dependent pathway is also triggered.

The results reported in Figure 1K implied that a major reshuffling of CD44 function occurred in SJL/J T cells upon TLR2 stimulation. We therefore tested the hypothesis that such a stimulus was also modifying the composition of the CD44 repertoire. In a first type of experiments, we examined the effect of TLR2 engagement on CD44 in the presence of cognate stimulation ( $\alpha$ CD3/ $\alpha$ CD28), mRNA specific for two isoforms, CD44<sub>v8-v10</sub> and, to a much higher extent, CD44<sub>v9-v10</sub> were selectively promoted, especially in CD4<sup>+</sup>CD62L<sup>low</sup> T cells (Figures 2A and 2B). Next, we examined the role of each stimulus, individually (cognate, TLR2/TLR6 dimer, and TLR2/TLR1 dimer), only in CD4<sup>+</sup>CD62L<sup>low</sup> T cells (Figure 2C panel). Cognate activation alone led to a modest up-regulation of mRNA specific for isoform CD44<sub>v9-v10</sub>. Additional stimulation of TLR2 led to a much stronger upregulation of mRNAs specific for isoforms CD44<sub>v8-v10</sub> and CD44<sub>v9-v10</sub>.

However, the type of TLR2 dimer triggered alternatively spliced CD44 pre-mRNA. In fact, mRNA specific for isoform CD44<sub>v9-v10</sub> was upregulated via activation of TLR2/TLR6 (PAM2/CSK4) and of TLR2/TLR1 (PAM3/CSK4), whereas mRNA specific for isoform CD44<sub>v8-v10</sub> was upregulated only by TLR2/TLR1 dimer. Together, our results show that signals coming from TCR and from TLR2 reshuffled the alternative splicing of pre-mRNA specific for CD44, with a pattern depending on the type of dimer involvement.

### T cells from C57Bl/6 mice selectively upregulated mRNA specific for isoform CD44<sub>v8-v10</sub> in a TLR2(I82M)-dependent manner

We have previously shown that the ability of *Mtb* to modulate trafficking properties of CD4<sup>+</sup> T cells was regulated in a strain-specific manner and depends on a single non-synonymous polymorphism at position 82 of TLR2 (Piermattei et al., 2016). The levels of CD44 on T cell surface was modified according to TLR2 polymorphism (Figure 1E). We therefore next examined if mouse strain and TLR2 polymorphism have a role on the alternative splicing of pre-mRNA specific for CD44.



**Figure 2. TLR2 activation modulated CD44 alternative splicing, promoting upregulation of isoforms CD44<sub>v8-v10</sub> and CD44<sub>v9-v10</sub> in SJL/J strain and only isoform CD44<sub>v8-v10</sub> in C57Bl/6 strain**

(A and B) CD4<sup>+</sup>CD62L<sup>low</sup> and CD4<sup>+</sup>CD62L<sup>high</sup> cells were isolated from the spleens of naïve female SJL/J (n = 5) and stimulated with αCD3/αCD28, PAM2/CSK4, and PAM3/CSK4. The repertoire of CD44 mRNA isoforms was analyzed by RT-qPCR. A consistent upregulation of CD44<sub>v9-v10</sub> and a slighter upregulation of CD44<sub>v8-v10</sub> occurred upon stimulation of CD4<sup>+</sup>CD62L<sup>low</sup> T cells with αCD3/αCD28 and PAM2/CSK4 or PAM3/CSK4.

(C and D) TLR2/6 and TLR2/1 display non-overlapping abilities to favor the production of CD44<sub>v8-v10</sub> and CD44<sub>v9-v10</sub> isoforms in SJL/J versus C57Bl/6 mice. CD4<sup>+</sup>CD62L<sup>low</sup> cells were isolated from the spleens of SJL/J (C) or C57Bl/6 (D) mice and stimulated as described. (C) PAM2/CSK4 or PAM3/CSK4 alone are both able to induce an upregulation of CD44<sub>v9-v10</sub> (Red Bars), albeit modest, but cognate stimulation plus TLR2 promotes a much stronger increase of both, CD44<sub>v8-v10</sub> (Green Bars) and CD44<sub>v9-v10</sub>, in SJL/J strain (n = 4). (D) Only isoform CD44<sub>v8-v10</sub> was upregulated in C57Bl/6 mice (n = 4) and required cognate stimulation.

(E and F) CD44 repertoire regulation on T cells in part depends on TLR2 polymorphism. CD4<sup>+</sup>CD62L<sup>low</sup> cells were isolated from the spleen of F1 SJL/J<sup>w/w</sup>x C57Bl/6<sup>w/w</sup> (n = 3, E) or F1 SJL/J<sup>w/w</sup>x C57Bl/6<sup>tlr2-/-</sup> (n = 3, F) mice, and stimulated as described in the figure. Data show that TLR2 of SJL/J is able to restore the expression of isoform CD44<sub>v9-v10</sub> when C57Bl/6 TLR2 is not present (F). All data are shown as mean ± SD.

The regulation of alternative splicing of pre-mRNA of *CD44* differed in C57Bl/6 mice compared to SJL/J mice. In fact, both TLR2/TLR1 and TLR2/TLR6 dimers upregulated effectively and to the same extent the production of mRNA specific for isoform *CD44<sub>v8-v10</sub>*, while production of mRNA specific for isoform *CD44<sub>v9-v10</sub>* was not upregulated above the 2-fold threshold by any of the two dimers (Figure 2D panel).

To evaluate the contribution of TLR2 polymorphism at position 82 in the differences observed in the regulation of *CD44* pre-mRNA splicing, we next examined *CD44* regulation on T cells from F1 (SJL/J<sup>wt</sup> × C57Bl/6<sup>wt</sup>, which have TLR2 from both SJL/J<sup>wt</sup> (82Ile) and C57Bl/6<sup>wt</sup> (82Met)), versus F1 (SJL/J<sup>wt</sup> × C57Bl/6<sup>tlr2<sup>-</sup></sup>) which have only TLR2 of SJL/J, as previously described by our group (Nicolò et al., 2013; Piermattei et al., 2016). The results (Figures 2E and 2F panels) indicated that TLR2 polymorphism together with other genetic traits play a role in determining the differences between the two mouse strains. In fact, the haplotype of SJL/J origin predominantly inhibited the upregulation of *CD44<sub>v8-v10</sub>*-specific mRNA by TLR2/TLR6 occurring when TLR2 of C57Bl/6<sup>wt</sup> origin is also present (Figure 2E), but was not sufficient to restore the ability of TLR2 to upregulate the production of mRNA specific for isoform *CD44<sub>v9-v10</sub>* (Figure 2C). However, when TLR2 of C57Bl/6<sup>wt</sup> origin was absent, the ability of TLR2/TLR6 dimers to upregulate the production of the mRNA specific for isoform *CD44<sub>v9-v10</sub>* was restored, although to a lower extent (Figure 2F).

In conclusion, these results show that while TLR2 regulates alternative splicing of *CD44*-specific pre-mRNA in both SJL/J<sup>wt</sup> and C57Bl/6<sup>wt</sup> mouse strains, the impact of TLR2 engagement on the relative composition of *CD44* repertoire depends on the TLR2 isoform present and on other strain-specific characteristics.


### Wnt/ $\beta$ -catenin pathway was regulated by strain background and TLR2

Several previous observations have shown that the Wnt/ $\beta$ -catenin system regulates *CD44* expression and its alternative splicing in human cells (Goncalves et al., 2008; Idris et al., 2019; Vallée et al., 2018). Particularly, these studies showed that TLR3 engagement inhibits the phosphorylation of  $\beta$ -catenin by favoring ubiquitination of GSK-3 $\beta$ , in a TRAF6-dependent manner. We therefore examined if engagement of TLR2 on mice-derived CD4<sup>+</sup>CD62L<sup>low</sup> T cells is also able to inhibit phosphorylation of  $\beta$ -catenin. The Western Blot analysis showed that the amount of total  $\beta$ -catenin was increased by 1-h stimulations via TLR2/6, TLR2/1, and  $\alpha$ CD3/ $\alpha$ CD28 (Figure 3A), while both TLR2 stimulations downregulated the levels of the phosphorylated form of  $\beta$ -catenin (Figure 3B). After 6 h of stimulation, total  $\beta$ -catenin showed to be still upregulated only by stimulus through TLR2/6 (Figure 3C), while phosphorylated  $\beta$ -catenin resulted downregulated by all stimuli (Figure 3D). Thus, TLR2 engagement immediately blocked the phosphorylation of  $\beta$ -catenin, thereby favoring total  $\beta$ -catenin accumulation and, consequently, its ability to translocate into the nucleus to act as a transcription factor.

To examine if the expression of all *Wnt*, and of  $\alpha$ - and  $\beta$ -catenins mRNAs is modulated in a strain and TLR2 haplotype-dependent manner, we retrospectively evaluated the RNA microarray analysis of lymph node CD4<sup>+</sup> T cells from SJL/J, F1 (SJL/J<sup>wt</sup> × C57Bl/6<sup>tlr2<sup>-</sup></sup>), and F1 (SJL/J<sup>wt</sup> × C57Bl/6<sup>wt</sup>) mice, reported here and in our previous work (Piermattei et al., 2016). Results are reported in Figures 3E–3I.

mRNAs levels specific for *Wnt-10a* and *Wnt-16* (Figures 3E and 3F) did not differ between the two F1 mice, but both significantly differed from the parental SJL/J mice (One-way ANOVA test,  $p = 0.004$  for SJL<sup>tlr2<sup>-</sup></sup> vs parental SJL/J and  $p = 0.006$  for SJL × C57Bl/6 vs parental SJL/J in *Wnt-10*; one-way ANOVA test,  $p = 0.02$  for SJL<sup>tlr2<sup>-</sup></sup> vs parental SJL/J and  $p = 0.04$  for SJL × C57Bl/6 vs parental SJL/J in *Wnt-16*) indicating that regulation of these factors depended on the mouse strain (SJL/J vs SJL/J × C57Bl/6). Levels of mRNA specific for *Wnt-10b* (Figure 3G) showed no differences between the SJL/J and F1 hybrids (SJL/J<sup>wt</sup> × C57Bl/6<sup>wt</sup>, one-way ANOVA test,  $p = 0.11$ ) mice, but both differed from the F1 (SJL/J<sup>wt</sup> × C57Bl/6<sup>tlr2<sup>-</sup></sup>, one-way ANOVA test,  $p = 0.04$ ) mice, indicating that regulation of that factor depended on gene dosage of *TLR2*.

Finally, we found no difference in mRNA levels for  $\alpha$ -catenin1 (Figure 3H) between the SJL/J and F1 hybrids (SJL/J<sup>wt</sup> × C57Bl/6<sup>tlr2<sup>-</sup></sup>, one-way ANOVA test,  $p = 0.8$ ) mice, while they showed to differ between SJL/J and the F1 hybrids (SJL/J<sup>wt</sup> × C57Bl/6<sup>wt</sup>) mice (one-way ANOVA test,  $p = 0.03$ ), thus indicating that regulation of this factor depended on the reported polymorphism of TLR2 between SJL/J and C57Bl/6 strains. Finally, the level of mRNA specific for  $\beta$ -catenin (Figure 3I) appeared to be significantly different between the



**Figure 3. TLR2 interacts with the Wnt/ $\beta$ -catenin pathway and promotes the expression of splicing factors involved in the CD44 alternative splicing** (A–D) Stimulation of TLR2/1 and TLR2/6 dimers blocks phosphorylation of  $\beta$ -catenin. CD4<sup>+</sup>CD62<sup>low</sup> T cells were enriched from the spleens of naive SJL/J mice (n = 3) and stimulated as described with PAM2/CSK4, PAM3/CSK4, or  $\alpha$ CD3/ $\alpha$ CD28 microparticles, for 1 (A and B) or 6 (C and D) hours. Proteins were purified and examined by Western blot for total (A and C) and phosphorylated (B and D)  $\beta$ -catenin (displayed data are the result of a single Western Blot assay). (E–I) The wnt/ $\beta$ -catenin pathway is influenced by strain, TLR2 gene dose, and TLR2 haplotype. Five SJL/J<sup>tlr2 82M/M</sup> (deep blue bars), six SJL/J<sup>tlr2 82M/-</sup> (light blue bars), and six SJL/J<sup>tlr2 82M/l</sup> (red bars) were challenged s.c. with CFA containing 50  $\mu$ g/mouse of heat-inactivated *Mtb*. Microarray analysis was performed on CD4<sup>+</sup> cells enriched from draining LN 4 days after immunization. Data are normalized versus the highest value obtained for each mRNA. Significance of the differences was evaluated by one-way ANOVA and Tukey HSD test. Values (mean + SD) are shown for Wnt10a (A), Wnt16 (B), Ctnn1 (C), Wnt10b (D), and  $\beta$ -catenin (E).

(J) Splicing factors prediction through SFMAP software. Following the methodology of Paz et al. (Paz et al., 2010) and using the software SFMAP at <http://sfmap.technion.ac.il>, it has been possible to predict the splicing factors most probably involved in the alternative splicing of CD44<sub>v9-v10</sub> and CD44<sub>v8-v10</sub> (red circles indicate the most relevant ones).

(K–P) TLR2 stimulation changes mRNAs of the splicing factors NOVA-1, SRSF3, and YB-1 in SJL/J-derived but not in C57Bl/6-derived T cells. T cells isolated from SJL/J (K–M, n = 3) or C57Bl/6 (N–P, n = 4) were stimulated with PAM2/CSK4, PAM3/CSK4, or  $\alpha$ CD3/ $\alpha$ CD28 microparticles (data are shown as fold increase  $\pm$  SD and normalized on unstimulated cells). As potentially involved in the alternative splicing of CD44 favoring the production of CD44<sub>v9-v10</sub> mRNA specific of three splicing factors, NOVA-1 (K and N), SRSF3 (L and O), and YB-1 (M and P) has been tested in RT-qPCR. Although differently depending on the stimulus, the three splicing factors resulted consistently upregulated in the SJL/J strain (one-way ANOVA statistical analysis showed a significant p = 0.03 for SRSF-3, unstimulated vs  $\alpha$ CD3/ $\alpha$ CD28 stimulated cells), while no relevant upregulation was observed in the C57Bl/6 strain, in which in most conditions is shown a downregulation of the same splicing factors.

parental SJL/J and the hybrid SJL<sup>tlr2-</sup> (one-way ANOVA test, p = 0.005), while no difference was found between SJL/J and the hybrid F1 (SJL/Jx C57Bl/6, one-way ANOVA test, p = 0.11).

### Engagement of TLR2 modulated the levels of mRNAs specific for CD44 splicing factors

Based on the DNA sequence of CD44 at the splicing site leading to the generation of CD44<sub>v9-v10</sub> isoform, we next used a computational approach to determine the most likely splicing factors involved in the



production of *CD44<sub>v9-v10</sub>* and *CD44<sub>v8-v10</sub>* (Figure 3J). We found that three splicing factors (Nova-1, Srsf3, and Yb-1) were potentially involved in the splicing of mRNA to produce *CD44<sub>v9-v10</sub>* (Paz et al., 2010). As a support of the validity of this approach, one of these factors, Srsf3, has previously been shown to be regulated by  $\beta$ -catenin, in cancer cells (Bordonaro, 2013; Goncalves et al., 2008; Idris et al., 2019; Thorsen et al., 2011). Therefore, we compared modulation of their expression in *CD4<sup>+</sup>CD62<sup>low</sup>* T cells of SJL/J and C57Bl/6 mice. Each stimulus was able to produce a distinct modulation—mostly an upregulation—of the mRNAs specific of the three splicing factors, in the absence or presence of the cognate stimulus, in the SJL/J mouse (Figures 3K–3M). Confirming our observation that C57Bl/6 mice failed to upregulate isoform *CD44<sub>v9-v10</sub>*, none of the condition tested led to upregulation of *NOVA-1*, *SRSF3*, or *YB-1* in T cells derived from this latter strain. Rather, in most conditions, TLR2 stimulation resulted in a downregulation of the levels of mRNA specific for the splicing factors tested (Figures 3N–3P). Thus, we cannot exclude that all tested splicing factors alone or in combination regulate the selective production of *CD44<sub>v9-v10</sub>* isoform.

Taken together, the observations reported in Figure 3 corroborated the hypothesis of the existence of a pathway connecting TLRs via  $\beta$ -catenin to alternatively spliced CD44, as previously shown in cancer cells (Todaro et al., 2014).

### Engagement of TLR4 and TLR9 led to modification of alternative splicing of CD44 pre-mRNA

In addition to TLR2, activated T cells also express TLR4 and TLR9. As all TLRs share the common signaling pathway that relies on adaptor protein MyD88, we assessed if also triggering of these other two TLRs could lead to reshuffling of the repertoire of the *CD44*-specific mRNA. We therefore stimulated isolated, SJL/J-derived T cells with CpG (selective ligand for TLR9), LPS (for TLR4), and PPD (as a mainly TLR2-restricted ligating agent). Results are reported in Figure 4A. As expected, stimulation with PPD resulted in the upregulation of isoforms *CD44<sub>v9-v10</sub>* and *CD44<sub>v8-v10</sub>*, that was also dependent on the simultaneous cognate interaction. Stimulation with LPS and CpG led to modifications of the landscape of the *CD44* isoform-specific mRNAs, which were distinct from those generated by engagement of TLR2. These results led to three main observations: first, induction of alternative splicing by LPS and CpG did not depend on  $\alpha$ CD3/ $\alpha$ CD28 microparticles stimulation; second, stimulation by both LPS and CpG led to upregulation also of mRNA specific for isoform *CD44<sub>v1-v10</sub>*, which was never promoted by TLR2; third, stimulation by LPS failed to promote the production of mRNA specific for isoform *CD44<sub>v8-v10</sub>* also when T cells were simultaneously stimulated via CD3/CD28.


We also tested in RT-qPCR the mRNA levels of the splicing factors *NOVA-1*, *SRSF-3*, and *YB-1* in SJL/J (upper panel) and C57Bl/6 (lower panel) strains upon stimulation with CpG (Figure 4B) or LPS (Figure 4C), in presence or absence of cognate stimulation with  $\alpha$ CD3/ $\alpha$ CD28 beads. Data showed that CpG, alone and together with  $\alpha$ CD3/ $\alpha$ CD28 particles, was able to upregulate all the three splicing factors in the SJL/J strain, while any relevant difference was observed in the C57Bl/6 one. The same observations were reported in the mRNA level analysis of these splicing factors upon stimulation with LPS.

Thus, albeit signals from all TLRs converge on the MyD88 pathway, each pathogen receptor promoted a specific pattern of mRNAs specific for the various isoforms of *CD44*.

### Cells infiltrating the forebrain at the onset of EAE overexpressed CD44<sub>v9-v10</sub>

We previously reported that the polymorphism TLR2<sup>IB2M</sup> influences the distribution of immune infiltrates in the CNS, with TLR2<sup>IB2M</sup> promoting the presence of lesions in the forebrain and TLR-2<sup>82M</sup> dominantly preventing it (Piermattei et al., 2016). Because TLR2 polymorphism led to differences in the processing of *CD44* pre-mRNA as shown above, we next examined the hypothesis that isoforms *CD44<sub>v9-v10</sub>* and *CD44<sub>v8-v10</sub>* distributed differently in the various areas of the CNS during EAE. We therefore examined the amount of mRNA specific for the *CD44* isoforms in four distinct sections of the CNS: caudal spinal cord, upper spinal cord, cerebellum, and forebrain at EAE onset. The amount of mRNA specific for *CD44s* was used as a measure of the number of infiltrating cells in each section. Therefore, to assess if any preferential expression of these isoforms existed among cells infiltrating each section, we compared the distribution of mRNA specific for isoforms *CD44<sub>v8-v10</sub>* or *CD44<sub>v9-v10</sub>*, normalized for *CD44s* (results are shown in Figures 5A and 5B).

We observed that the expression of *CD44s*-specific mRNA was similar in caudal CNS, while it was 10-fold lower in forebrain (Figure S2A). Likewise, the expression level of mRNAs specific for *IL1 $\beta$*  and *IL6*




**Figure 4. Stimulation of TLR4, TLR9 modulated alternative splicing of CD44 in the SJL/J strain**

(A–C) Because activated T cells also express TLR4 and TLR9,  $CD4^+CD62^{low}$  T cells from SJL/J ( $n = 3$ ) were stimulated with LPS (TLR4), CpG (TLR9), and PPD (as a mainly TLR2-restricted ligating agent). mRNA of *CD44* isoforms was analyzed by RT-qPCR. Compared to unstimulated condition, isoforms *CD44*<sub>v1-v10</sub> and *CD44*<sub>v9-v10</sub> resulted upregulated by LPS and CpG alone or in combination with  $\alpha$ CD3/ $\alpha$ CD28 microparticles (A). RT-qPCR analysis also showed that CpG and LPS modulate in distinct ways the splicing factors *NOVA1*, *SRSF3*, and *YB-1* (B and C, upper panels, respectively). mRNA of  $CD4^+CD62^{low}$  T cells from C57Bl/6 mice (B and C, lower panels), stimulated in the same ways, were also analyzed and the stimulation resulted in down-regulation of the three splicing factors (data are normalized on unstimulated cells and displayed as fold increase  $\pm$  SD).

(as indicators of the ongoing inflammatory response) showed the same distribution of *CD44s* (Figures 5C and 5F).

Supporting our hypothesis, the ratio between *CD44*<sub>v9-v10</sub> and *CD44s*-specific mRNAs was significantly higher in the forebrain with respect to the other CNS areas (Figure 5A, one-way ANOVA test, forebrain vs caudal SC  $p = 0.02$ , forebrain vs upper SC  $p = 0.04$  and forebrain vs cerebellum  $p = 0.03$ ). On the contrary, *CD44*<sub>v1-v10</sub>, *CD44*<sub>v4-v10</sub>, and *CD44*<sub>v8-v10</sub> were expressed in all examined areas at the same relative concentration (one-way ANOVA test, all  $p$  values resulted  $p \geq 0.7$ ), excluding any specific association of other isoforms with cells homing preferentially to any CNS area (Figures S2B and S2C and 5B, respectively).

The observations reported in Figures 5C–5F could be explained by differences in clonal composition or in the T-helper phenotype of the T cell repertoire infiltrating the PFC. The analysis of  $CD4^+$  (Nicolò et al., 2006) and  $CD8^+$  (Penitente et al., 2008) clonotypes in the CNS (Figure 5G) shows that T cells infiltrating the forebrain did not belong to a single clonotype. Likewise, cells infiltrating the forebrain do not have a distinct cytokine phenotype and did not show any selective enrichment for Th1 or Th17 cells (Figures 5D and 5E).



**Figure 5. EAE SJL/J mice showed CD44<sub>v9-v10</sub> overexpression in the forebrain at the onset of the disease, and TLR stimulation modifies the binding of CD44 to osteopontin**

(A–J) Central nervous systems from SJL/J mice (n = 4) at the onset of EAE were harvested and divided into four areas: caudal spinal cord (red bar), upper spinal cord (orange bar), cerebellum (dark red bar), and forebrain (purple bar). CD44 isoforms were analyzed by RT-qPCR and normalized to the mRNA specific for CD44s. A significant upregulation of isoform CD44<sub>v9-v10</sub> was observed in the forebrain (A) compared to the caudal spinal cord (two-way ANOVA, Tukey's multiple comparisons test p = 0.02), the upper spinal cord (two-way ANOVA, Tukey's multiple comparisons test p = 0.04), and to the cerebellum (two-way ANOVA, Tukey's multiple comparisons test p = 0.03). No significant changes in the brain areas were observed for isoform CD44<sub>v8-v10</sub> (B).

Amount of mRNA specific for *IL-1β* (C), *INF-γ* (D), *IL-17* (E), and *IL-6* (F) has been evaluated and normalized to the mRNA specific for CD44s. (G–J) Presence of PLP<sub>139-151</sub>-specific clonotypic CD4<sup>+</sup> and CD8<sup>+</sup> cells in the CNS areas at the onset of EAE in the same samples. cDNA from the same samples were analyzed by CDR3BV-BJ spectratyping as described in (Nicolò et al., 2006). Enrichment of the indicated TCR-β rearrangement is reported as rate enrichment index (REI) for each brain area with the same code color used above.

(K) *In silico* modeling of CD44s, CD44<sub>v8-v10</sub>, and CD44<sub>v9-v10</sub>. Region corresponding to CD44<sub>v8-v10</sub> and CD44<sub>v9-v10</sub> are shown in yellow and violet, respectively.

(L) Calculated solvent accessible surface area (SASA) of isoforms CD44s (gray), CD44<sub>v9-v10</sub> (pink), and CD44<sub>v8-v10</sub> (yellow). All SASA values of CD44<sub>v9-v10</sub> resulted significantly higher compared to the ones of CD44s and CD44<sub>v8-v10</sub> (one-way ANOVA test, p < 0.0001).

(M) TLR2 stimulation modifies interaction of T cells with osteopontin in a CD44-dependent manner. CD4<sup>+</sup>CD62L<sup>low</sup> T cells were isolated from SJL/J spleen (n = 4 mice) and stimulated as described in the figure. T cells were plated on Matrigel® pre-coated with OPN and stimulated with PAM2/CSK4, PAM3/CSK4, and/or by αCD3/αCD28-coated microparticles, in the presence (red bars) or absence (green bars) of α-pan-CD44 mAb. After 6 h, cells that passed the Matrigel® were counted by flow cytometry. Data are expressed as number of cells recovered in the lower chamber. Statistical analysis was performed by two-way ANOVA, Tukey's multiple comparisons. All data are shown as mean ± SD. Only significant p values are displayed.

Taken together, these data show that CD44<sub>v9-v10</sub> promotes T cell homing in the forebrain. However, we did not find any evidence for a clonal or functional limitation of its expression and the available data do not suggest a mechanism for which isoform CD44<sub>v9-v10</sub> is upregulated *in vivo* selectively only on particular T cell subsets.

All CD44 isoforms share the same ligand-binding domain and juxta- and intracellular domains. Yet, we observed that expression of isoform CD44<sub>v9-v10</sub> was enriched on some cells that are prone to infiltrate the forebrain. Such observation implies that upregulation of this isoform modifies the binding of CD44 to some ligand(s) differentially expressed in the extracellular matrix of distinct CNS areas.

To address this, the three-dimensional structural models of the three isoforms of CD44, CD44s, CD44<sub>v9-v10</sub>, and CD44<sub>v8-v10</sub> (Figure 5K) were generated and investigated by *in silico* approaches (Figures S3A and S3B). The best scoring models displayed a C-score value of -1.07, -0.67, and -1.75 for CD44s, CD44<sub>v8-v10</sub>, and CD44<sub>v9-v10</sub>, respectively. Figure 5L shows that, upon insertion of the 98 residues, the global SASA of the CD44<sub>v9-v10</sub>N-terminal domain decreased, if compared to CD44s (16,263 ± 334 Å<sup>2</sup> and 14,793 ± 502 Å<sup>2</sup>, respectively). A comparable reduction is observed for the hydrophobic and polar SASA components.

Interestingly, the CD44<sub>v8-v10</sub>N-terminal domain displayed SASA values significantly higher (one-way ANOVA test, p < 0.0001) than the two other isoforms (17,361 ± 833 Å<sup>2</sup>, 6,231 ± 234 Å<sup>2</sup>, and 11,130 ± 705 Å<sup>2</sup> for global, hydrophobic, and polar components, respectively). Considering that the SASA quantifies the isoform exposure to solvent molecules, the observed differences support the hypothesis that the various CD44 isoform are characterized by a different interaction pattern with ligands.

CNS extracellular matrix contains several ligands of CD44 under non-inflammatory conditions, and can be further modified by inflammation, e.g., through the action of metalloproteinases. Yet, few reports show differences in individual matrix proteins along the various areas. As shown in Figure 5M, we observed that TLR stimulation reshuffles the role of CD44 in the binding to low MW hyaluronic acid, the main constituent of Matrigel. Osteopontin (OPN) was observed to display distinct immunoreactivity in frontal versus caudal areas of human CNS, hinting distinct isoforms as its possible ligands (under normal conditions) in driving the specific homing of T cells. On the other hand, type I collagen (Coll I) has been shown to be present in the perivascular spaces of CNS and thus could be potentially involved in T cell migration.

The results of migration assay on Matrigel enriched with OPN (Figure 5M) demonstrated that TLR2/6 and αCD3/αCD28 stimuli increase the adhesion of CD44 to OPN. In fact, anti-CD44 antibody blocked migration of T cells through OPN-coated Matrigel, in unstimulated cells. Thus, in the absence of any further stimulation, OPN favors CD62<sup>low</sup>T cell crossing in a CD44-dependent manner. Stimulation by αCD3/αCD28 reduces the crossing which is only modestly (or not at all) restored by αCD44. Thus, upon stimulation with αCD3/αCD28, there is an apparent loss of the role of OPN/CD44 binding in promoting T cell trafficking across Matrigel. When we further add PAM2/CSK4, we invert the effect of binding between OPN and

**Table 1. Demographic, clinical, and laboratoristic data of patients with MS for CSF analysis**

	RR-MS patients N=34
Sex, n of female (%)	24 (70.5)
Age, years (mean $\pm$ SD)	37.8 $\pm$ 10.4
Disease Duration, mo. (mean $\pm$ SD)	27,2 $\pm$ 49.4
EDSS (mean $\pm$ SD)	1,51 $\pm$ 0.97
Previous attacks, n of patients (%)	27 (79.4)
Relapse within 3 months, n of patients (%)	12 (35,3)
CSF - OB, n of patients (%)	25 (73,4)
ESR, mm/h (mean $\pm$ SD)	9.6 $\pm$ 9.0
CRP, mg/dl (mean $\pm$ SD)	2.6 $\pm$ 7.1
CSF protein, mg/dl (mean $\pm$ SD)	29.1 $\pm$ 10.3
CSF glucose, mg/dl (mean $\pm$ SD)	61.2 $\pm$ 9.9
IgG index (mean $\pm$ SD)	0.95 $\pm$ 0.59
MRI+, n of patients (%)	5 (14.7)
Total GDP+, n of patients (%)	20 (58.8)
Encephalic GDP+, n. of patients (%)	19 (55.9)


EDSS: expanded disability status scale; Previous attacks are intended as a number of two or more attacks preceding the study entry (day of diagnosis). Relapse within three months is intended within 3 months from the study entry (day of enrollment). CSF: Cerebrospinal Fluid; OB: Oligoclonal Bands; ESR: ErythroSedimentation Rate; CRP: C Reactive Protein; MRI+: MRI positive lesions in the spinal cord at study entry (day of diagnosis); Total and encephalic GDP+: Gadolinium phosphide-enhancing positive lesions in both spinal cord and encephalon, or only encephalon at study entry (day of diagnosis).

CD44, because now  $\alpha$ CD44 promotes T cell migration. Thus, simultaneous stimulation with  $\alpha$ CD3/ $\alpha$ CD28 and PAM2/CSK4 modifies the role of OPN/CD44 binding blocking T cells in the upper chamber or within the gel itself. As a control of specificity, binding to type I collagen was increased by the same stimuli, but in this case blocking CD44 did not reverse this effect (Figure S4). Thus, our data suggest that reshuffling of CD44 role in T cell trafficking possibly affected its ability to bind to OPN.

### Human CD44<sub>v7</sub>-specific mRNA expressed in cells from CSF of patients with MS associated with presence of gadolinium-enhancing lesions

The data reported above in the mouse model suggested that CD44 isoforms might play a role in addressing T cells selectively to (distinct) CNS compartments. We therefore examined if the repertoire of mRNAs specific for CD44 isoform variants in all the type of cells obtained from human CSF of patients with MS (Table 1) showed any sign of skewing. In Figure 6A, we report that the expression of CD44<sub>v7</sub> and CD44<sub>v8</sub>-specific mRNAs appear to have a bimodal distribution of values. Samples were divided into two roughly equivalent groups for CD44<sub>v7</sub><sup>high</sup> and CD44<sub>v7</sub><sup>low</sup> values, while high values for CD44<sub>v8</sub> mRNA were expressed only by a small subgroup of samples. We did not find a correlation of mRNA expression levels among CD44<sub>v7</sub> or CD44<sub>v8</sub> and nuclear factors or cytokines characterizing Th cell phenotype, further supporting our findings in the mouse model. Although high expression of CD44<sub>v8</sub> and s (and of any other variant CD44) was not found to be related to any clinical feature (Figures 6B and 6D), CD44<sub>v7</sub><sup>high</sup> patients with MS show active inflammatory lesions, detected as gadolinium-enhancing lesions (GELs) at the CT scan (Figure 6C), significantly more frequently than CD44<sub>v7</sub><sup>low</sup> ones (Fisher's exact test, p = 0.031). Together, these observations suggest that regulation of CD44 alternative splicing is involved in disease development not only in the EAE model as shown above, but also in the pathogenesis of neuroinflammation in MS.

We next evaluated if TLRs were able to modulate the repertoire of CD44 isoforms in human T cells also, with a special reference to -v7 and -v8. We therefore isolated CD4<sup>+</sup>CD62<sup>low</sup> cells from peripheral blood of 9 patients with MS (4 GELs<sup>+</sup> and 5 GELs<sup>-</sup>) and three healthy donors (Table 2) and stimulated them with TLRs ligands in the presence or absence of biotinylated microparticles coated with human  $\alpha$ CD3/ $\alpha$ CD28/ $\alpha$ CD2 antibodies to mimic antigen-presenting cells and simulate the cognate interaction, as described above for mouse model. The results for -s, -v7, and -v8 isoforms are reported in Figure 6E and show that TLR ligands poorly modulated the repertoire of these CD44 variants in the absence of cognate stimulus. Instead, cognate stimulus alone drove a selective upregulation of mRNA specific for -v7, -v8 (and -v9)



**Figure 6. Alternative splicing of CD44 in human CD4<sup>+</sup> cells from patients affected by multiple sclerosis**

(A) Repertoire of alternatively spliced CD44<sub>vv</sub> in cells from CSF of patients with RR-MS (n = 34). Data are shown as mean ± SD.

(B–D) Correlation of CD44<sub>s</sub> (B), -v7 (C), and -v8 (D) expression (>median, full columns; <median, empty columns) in patients showing gadolinium-enhancing lesions (GEL<sup>+</sup>) in the CNS. Only CD44<sub>v7</sub> resulted to be significantly correlated (Fisher's exact tests, p = 0.031) to the presence of GEL<sup>+</sup>, while none of the other CD44 isoform showed to be related to any clinical features.

(E) mRNA expression levels of CD44<sub>s</sub>, v7, and v8 in CD4<sup>+</sup> human T cells stimulated with PAM2/CSK4, PAM3/CSK4, and/or  $\alpha$ CD3 $\alpha$ /CD28 and isolated from peripheral blood of patients with MS (N = 9) and healthy donors (N = 3). The colored bar indicates high or low expression of the three CD44 isoforms. No relevant differences were observed between GEL<sup>+</sup> (N = 4), GEL<sup>-</sup> (N = 5) patients with MS, and the healthy subjects in relation to CD44<sub>s</sub> and CD44<sub>v7</sub>, whereas CD44<sub>v8</sub> resulted mostly upregulated in patients with MS, independently of the presence of active lesions.

**Table 2. Demographic, clinical, and laboratoristic data of patients with MS for PBMC analysis**

	RR-MS patients N=9	Healthy donors N=3
Sex, n of female (%)	6 (66.6)	1 (33.3)
Age, years (mean $\pm$ SD)	31.8 $\pm$ 7.74	33.3 $\pm$ 7.09
Disease Duration, mo. (mean $\pm$ SD)	377.8 $\pm$ 552.5	NA
EDSS (mean $\pm$ SD)	1.11 $\pm$ 0.91	NA
Previous attacks, n of patients (%)	3 (33.3)	NA
Relapse within 3 months, n of patients (%)	5 (55.5)	NA
CSF - OB, n of patients (%)	8 (88.9)	NA
ESR, mm/h (mean $\pm$ SD)	5.2 $\pm$ 4.3	NA
CRP, mg/dl (mean $\pm$ SD)	0.51 $\pm$ 0.07	NA
CSF protein, mg/dl (mean $\pm$ SD)	31.5 $\pm$ 13.4	NA
CSF glucose, mg/dl (mean $\pm$ SD)	64.3 $\pm$ 8.5	NA
IgG index (mean $\pm$ SD)	0.86 $\pm$ 0.5	NA
MRI+, n of patients (%)	2 (22.2)	NA
Total GDP+, n of patients (%)	4 (44.4)	NA
Encephalic GDP+, n. of patients (%)	2 (22.2)	NA

EDSS: expanded disability status scale; Previous attacks are intended as a number of two or more attacks preceding the study entry (day of diagnosis). Relapse within three months is intended within 3 months from the study entry (day of enrollment). CSF: Cerebrospinal Fluid; OB: Oligoclonal Bands; ESR: ErythroSedimentation Rate; CRP: C Reactive Protein; MRI+: MRI positive lesions in the spinal cord at study entry (day of diagnosis); Total and encephalic GDP+: Gadolinium phosphide-enhancing positive lesions in both spinal cord and encephalon, or only encephalon at study entry (day of diagnosis).

variants, and of the standard isoform (*CD44s*). In the presence of the cognate stimulus, TLRs ligands were able to further modulate the alternative splicing of *CD44* pre-mRNA in a TLR-specific fashion in a similar manner as in mouse T cells. However, the pattern of upregulated isoforms and the extent of stimulation was both variable among patients and controls. In general, cells from patients with MS appeared more prone to upregulating *CD44* isoforms following TLR and cognate stimulus than controls.

## DISCUSSION

In the present work, we defined a pathway through which infectious agents can directly modify trafficking properties of activated T cells.

*CD44* is a family of closely related molecules obtained by alternative splicing of a single pre-mRNA and by post-transcriptional modifications of its product. All *CD44* isoforms share the same ligand-binding site and *trans*-membrane and intracellular domains. The ligand-binding domain has a large repertoire of ligands, mostly consisting of the extracellular matrix molecules (Ponta et al., 2003). In general, it is believed that *CD44* increases the adherence of cells to the extracellular matrix, leading to variation in homing properties. Our observation that conditions leading to early mobilization of T lymphocytes from the LN associate with a decrease in the level of *CD44* expressed on the T cell surface is coherent with this hypothesis.

The complex modulation of alternatively spliced *CD44* pre-mRNA has been the object of several studies, mostly in tumor cells (Zhang et al., 2021). The largest array of information regards its "proximal" regulation, highlighting the role of factors of the spliceosome in the production of variant isoforms of *CD44* (Filippov et al., 2007; Goncalves et al., 2008; Loh et al., 2015; Midgley et al., 2017; Tripathi and Zhang, 2017). Although beyond the aim of current research, we highlighted a limited number of intermediate signaling pathways that led to modifications of *CD44* alternative splicing. Work from several groups converge on a prominent role for the  $\beta$ -catenin pathway in regulating *CD44* alternative splicing (Goncalves et al., 2008; Jiang et al., 2013; Todaro et al., 2014). It has been reported that TLR3 through TRAF-6 blocks the phosphorylation of  $\beta$ -catenin by ubiquitination of GSK-3 $\beta$  (Ko et al., 2015). Furthermore,  $\beta$ -catenin acts as a transcription factors for several splicing factors such as, among others, SRSF3 that has already been demonstrated to be involved in *CD44* alternative splicing in cancer (Bordonaro, 2013; Goncalves et al., 2008; Thorsen et al., 2011). Our data indicate that this pathway is also operating in activated CD4<sup>+</sup> T cells, where TLRs activation

(frequently in tandem with cognate interaction) was able to block  $\beta$ -catenin phosphorylation and upregulated (at least in the SJL/J strain) the expression of three splicing factors, *Nova-1*, *Yb-1*, and *Srsf3*.

In addition, here we reported also that strain background and TLR2 haplotype (the genetic factors that modulate CD44 splicing) modulated the expression of mRNAs specific for proteins involved in the  $\beta$ -catenin pathway.

To the best of our knowledge, ours is the first report showing a role for TLRs in the regulation of CD44 alternative splicing, and on its regulation in T lymphocytes. We showed that several conditions concurred to determine the outcome in terms of CD44 repertoire, both in mouse and human: activation status, co-occurrence of the cognate interaction, type of TLR involved. In preliminary experiments, with both TLR2 and MyD88 KO mice, we observed absence of upregulation of isoform CD44<sub>v8-10</sub>, that occurs upon stimulation with PAM2/CSK4 of T cells from the C57Bl/6 mouse (Figure S5). Taken together, our results suggest that the pathway of signaling leading to reshuffling of the CD44 repertoire may proceed from TLR(s), through MyD88 to  $\beta$ -catenin and splicing factors (Martino et al., 2016).

CD44 variants are expressed by several types of cells, and in a cell-specific pattern (Weidle et al., 2011). In humans, lymphocytes express variant v6, i.e., the CD44 isoform that uses only exon 11. Variant v6 and other variants also encompassing exon 11 are also expressed by cancer cells with high metastatic potential, suggesting that the region encoded by exon 11 is involved in lymphocytes homing to LNs. Accordingly, here we report that a decreased expression of CD44 associates with early exit of T cells from LN and that upon antigen stimulation, blockade of CD44 increases the number of T cells able to cross Matrigel *in vitro*. In all experiments reported here in the mouse model, we observed a reduction of the expression levels of CD44s when cognate and TLR-mediated stimuli are simultaneously provided to T cells. However, we also show that a shift of the CD44 repertoire, promoting the expression of CD44<sub>v9-v10</sub>, occurs in these T cells. Moreover, this modification seemed to contribute to the mechanism(s) of crossing of Matrigel in a strain-specific manner. Overall, these data indicate that trafficking of T cells during immune responses is modulated in two distinct ways, by decreasing the expression of CD44 (presumably, mainly CD44s) and by reshuffling its isoform repertoire. Individual genetic variations of CD44 or in the regulation of splicing factors favor one mechanism over the other, as apparently verified in our studies in mice with SJL/J versus C57Bl/6 genetic background.

CD44 plays a dominant role in the ability of immune cells to enter the CNS. A detailed characterization of the distribution of 44-cell surface markers on cells from brain immune compartments indicated that expression of CD44 was the hallmark of all immune cells derived from the blood and able to enter the CNS in non-inflammatory conditions (Korin et al., 2017). CD44 collaborates with CD49 for the infiltration of CNS by leukocytes during EAE, and treatment with anti-CD44 blocks the development of the disease (Brennan et al., 1999). We observed that the presence of inflammatory infiltrates in the forebrain during EAE depends on TLR2 polymorphism at position 82 (Nicolò et al., 2013); we show here that the same polymorphism regulates specifically the production of CD44<sub>v9-v10</sub> isoform, that in turn associated specifically to cell licensed to infiltrate the forebrain at the onset of EAE. Our results also indicate that TLR2 stimulation modified the binding of CD44 to OPN. OPN has a complex role, acting as an extracellular matrix protein, as well as a chemokine and cytokine. Interestingly, OPN is present in different isoforms along the CNS. Thus, we can reasonably propose that a CD44 isoform (most likely, v9-v10) could drive the selective homing of T cells into specific areas of the CNS by interacting with one specific isoform of OPN.

It is known that infectious episodes often drive flares of MS (Perry et al., 2007). The distribution of infiltrates and lesions during MS is particularly unpredictable within each acute bout of disease and over time, along the course of MS (Lindner et al., 2018). Our observations illustrate this mechanism for infectious agents in the determination of autoimmune diseases, adding to those of molecular mimicry and T cell phenotype modulation that were reported by Miyauchi and collaborators (Miyauchi et al., 2020), and that we suggested a few years ago in our previous work in which infection with a non-pathogenic *mycobacterium* cross-reactive with PLP<sub>139-151</sub> was able to induce EAE (Nicolò et al., 2010). Here, we report that TLRs represent a path through which commensals as well as pathogenic infectious agents can modulate trafficking properties of T cells, ultimately leading to infiltration of the CNS. Our observation suggests that infectious agents can play a role in determining the distribution of lesions, acting along the pathway described in this work. In real life situation, however, the relation infectious agent-CNS infiltration will possibly be less linear, given the influence of individual genetic background and of the concomitant presence of a large commensal infectious flora.



The use of anti-CD44 antibodies in human therapy leads to development of severe side effects (Tijink et al., 2006), while the effectiveness of treatment with anti-CD49 of MS shows that interfering with the specific pathways involved in T cell trafficking into the CNS is a promising approach. Treatment aimed at the fine-tuning of the repertoire of CD44 or to prevent infiltration of leukocytes at specific sites may provide new tools for the treatment of MS and other autoimmune diseases.

In conclusion, our data show that pathogens and commensals can modify trafficking properties of activated T lymphocytes, by engaging TLRs and modifying the repertoire of CD44 isoforms. This pathway can play a relevant role in the determination of flares and/or remission of autoimmune diseases, even in the absence of direct cross-recognition by previously activated, self-specific T cells, potentially representing a new target for the therapy of brain inflammatory diseases. Future perspectives of this work and its possible evolutions will aim to explain the complex topic of the causative relations of each single alternatively spliced CD44v in regulating T cell trafficking, exploring, for example, the influences of simultaneous expression of the standard isoform or of other isoforms on the same cell, or the interaction of other adhesion molecules such as (e.g.) CD49, or dissecting the impact of still poorly studied splicing factors specifically involved in the modulation of alternative splicing of CD44.

### Limitations of the study

As stated above, ours is the first report describing a TLRs alternatively spliced CD44 axis in T lymphocytes. Although we suggest that the pathway of signaling leading to reshuffling of the CD44 repertoire possibly proceeds from TLR(s), through MyD88 to  $\beta$ -catenin and splicing factors, the specific pathway(s) downstream TLR has still to be fully described and detailed because engagement of different TLRs appears to lead to different CD44 isoforms repertoires. Moreover, we focused on T cells and on a specific disease model, but CD44v are also expressed by other cell types, also involved in autoimmune disorders. Thus, we expect that the mechanism here hypothesized is more complex and deserves to be deepened. Although we identified the potential ligand(s) of CD44 isoform(s) in the CNS, this aspect should be expanded, testing other possible components of the ECM that could have different affinity for each CD44v or that could interact with them in a complex manner dependent on the target organ. Finally, our data on CSF and PBMC from a cohort of RR-MS patients, although confirming our observations on EAE model, showed differences in terms of splice variants, suggesting, despite a similar mechanism, substantial differences between human and experimental disease that deserves to be deepened.

### STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Human CSF and blood collection
  - Mice
- METHODS DETAILS
  - Animal procedures
  - Cell culture
  - Flow cytometry
  - RT-qPCR assays
  - Model building and simulation of molecular dynamics
  - Gene expression microarray
  - Western blot
- QUANTIFICATION AND STATISTICAL ANALYSIS

### SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.isci.2022.103763>.

## ACKNOWLEDGMENTS

This research was funded by linea D1 – Università Cattolica del Sacro Cuore and FISM (Fondazione Italiana Sclerosi Multipla) cod 2016/R/22 (FR and GDS) and co-financed with 5-per-mille public funding; European Research Council (ERC) advanced grant nr. 697 695714 IMMUNOALZHEIMER (GC).

## AUTHOR CONTRIBUTIONS

Conceptualization, F.R., G.D.S.; methodology, G.D.S.; software, G.D.S., M.T., C.C., D.P., M.Fi., M.R., M.F., B.R., M.C.D.R.; validation; formal analysis: M.T., G.D.S., M.V., C.C., C.M., M.C.G., E.G.; investigation; data curation: G.D.S., M.T., M.L., M.M., M.C.G.; writing—original draft preparation: F.R., G.D.S., M.F., G.C.; writing—review and editing, M.T., G.D.S., F.R., D.P., M.C.D.R., M.F., G.C., M.Fi., M.R., M.C.G., M.M.; visualization, F.R.; supervision, G.D.S., F.R.; project administration, G.D.S.; funding acquisition, G.D.S., F.R. All authors have read and agreed to the published version of the manuscript.

## DECLARATION OF INTERESTS

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Received: July 26, 2021

Revised: October 28, 2021

Accepted: January 7, 2022

Published: February 18, 2022

## REFERENCES

- Baaten, B.J., Li, C.-R., and Bradley, L.M. (2010). Multifaceted regulation of T cells by CD44. *Commun. Integr. Biol.* 3, 508–512.
- Bader, A.G., Felts, K.A., Jiang, N., Chang, H.W., and Vogt, P.K. (2003). Y box-binding protein 1 induces resistance to oncogenic transformation by the phosphatidylinositol 3-kinase pathway. *Proc. Natl. Acad. Sci. U. S. A.* 100, 12384–12389.
- Baker, D., and Amor, S. (2012). Publication guidelines for refereeing and reporting on animal use in experimental autoimmune encephalomyelitis. *J. Neuroimmunol.* 242, 78–83.
- Bordonaro, M. (2013). Crosstalk between Wnt signaling and RNA processing in colorectal cancer. *J. Cancer* 4, 96–103.
- Brennan, F.R., Mikecz, K., Glant, T.T., Jobanputra, P., Pinder, S., Bavington, C., Morrison, P., and Nuki, G. (1997). CD44 expression by leucocytes in rheumatoid arthritis and modulation by specific antibody: implications for lymphocyte adhesion to endothelial cells and synoviocytes *in vitro*. *Scand. J. Immunol.* 45, 213–220.
- Brennan, F.R., O'Neill, J.K., Allen, S.J., Butter, C., Nuki, G., and Baker, D. (1999). CD44 is involved in selective leucocyte extravasation during inflammatory central nervous system disease. *Immunology* 98, 427–435.
- Calvier, L., Demuth, G., Manouchehri, N., Wong, C., Sacharidou, A., Mineo, C., Shaul, P.W., Monson, N.L., Kounnas, M.Z., Stüve, O., et al. (2020). Reelin depletion protects against autoimmune encephalomyelitis by decreasing vascular adhesion of leukocytes. *Sci. Transl. Med.* 12, eaay7675.
- Camponeschi, C., De Carluccio, M., Amadio, S., Clementi, M.E., Sampaiolese, B., Volonté, C., Tredicine, M., Romano Spica, V., Di Liddo, R., Ria, F., et al. (2021). S100B protein as a therapeutic target in multiple sclerosis: the S100B inhibitor arundic acid protects from chronic experimental autoimmune encephalomyelitis. *IJMS* 22, 13558.
- Cao, L., and Malon, J.T. (2018). Anti-nociceptive role of CXCL1 in a murine model of peripheral nerve injury-induced neuropathic pain. *Neuroscience* 372, 225–236.
- Di Sante, G., Migliara, G., Valentini, M., Delogu, G., and Ria, F. (2013). Regulation of and regulation by CD 44: a paradigm complex regulatory network. *Int. Trends Immun.* 1, 33–41.
- Fagone, P., Mazzon, E., Cavalli, E., Bramanti, A., Petralia, M.C., Mangano, K., Al-Abed, Y., Bramati, P., and Nicoletti, F. (2018). Contribution of the macrophage migration inhibitory factor superfamily of cytokines in the pathogenesis of preclinical and human multiple sclerosis: *in silico* and *in vivo* evidences. *J. Neuroimmunol.* 322, 46–56.
- Fallarino, F., Gargaro, M., Mondanell, G., Downer, E.J., Hossain, M.J., and Gran, B. (2016). Delineating the role of Toll-like receptors in the neuro-inflammation model EAE. *Methods Mol. Biol.* 1390, 383–411.
- Filippov, V., Filippova, M., and Duerksen-Hughes, P.J. (2007). The early response to DNA damage can lead to activation of alternative splicing activity resulting in CD44 splice pattern changes. *Cancer Res.* 67, 7621–7630.
- Galluzzo, E., Albi, N., Fiorucci, S., Merigiola, C., Ruggeri, L., Tosti, A., Grossi, C.E., and Velardi, A. (1995). Involvement of CD44 variant isoforms in hyaluronate adhesion by human activated T cells. *Eur. J. Immunol.* 25, 2932–2939.
- Ghazi-Visser, L., Laman, J.D., Nagel, S., van Meurs, M., van Riel, D., Tzankov, A., Frank, S., Adams, H., Wolk, K., Terracciano, L., et al. (2013). CD44 variant isoforms control experimental autoimmune encephalomyelitis by affecting the lifespan of the pathogenic T cells. *FASEB J.* 27, 3683–3701.
- Giampietro, C., Deflorian, G., Gallo, S., Di Matteo, A., Pradella, D., Bonomi, S., Belloni, E., Nyqvist, D., Quaranta, V., Confalonieri, S., et al. (2015). The alternative splicing factor Nova2 regulates vascular development and lumen formation. *Nat. Commun.* 6, 8479.
- Goncalves, V., Matos, P., and Jordan, P. (2008). The -catenin/TCF4 pathway modifies alternative splicing through modulation of SRp20 expression. *RNA* 14, 2538–2549.
- Govindaraju, P., Todd, L., Shetye, S., Monslow, J., and Puré, E. (2019). CD44-dependent inflammation, fibrogenesis, and collagenolysis regulates extracellular matrix remodeling and tensile strength during cutaneous wound healing. *Matrix Biol.* 75, 314–330.
- Gross, C.C., Schulte-Mecklenbeck, A., Hanning, U., Posevitz-Fejfar, A., Korsukewitz, C., Schwab, N., Meuth, S.G., Wiendl, H., and Klotz, L. (2017). Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsets. *Mult. Scler. J.* 23, 1025–1030.
- Humphrey, W., Dalke, A., and Schulten, K. (1996). VMD: visual molecular dynamics. *J. Mol. Graph.* 14, 33–38, 27–28.
- Idris, M., Harmston, N., Petretto, E., Madan, B., and Virshup, D.M. (2019). Broad regulation of gene isoform expression by Wnt signaling in cancer. *RNA* 25, 1696–1713.

- Jiang, W., Crossman, D.K., Mitchell, E.H., Sohn, P., Crowley, M.R., and Serra, R. (2013). WNT5A inhibits metastasis and alters splicing of Cd44 in breast cancer cells. *PLoS ONE* **8**, e58329.
- Ko, R., Park, J.H., Ha, H., Choi, Y., and Lee, S.Y. (2015). Glycogen synthase kinase 3 $\beta$  ubiquitination by TRAF6 regulates TLR3-mediated pro-inflammatory cytokine production. *Nat. Commun.* **6**, 6765.
- Korin, B., Ben-Shaanan, T.L., Schiller, M., Dubovik, T., Azulay-Debby, H., Boshnak, N.T., Koren, T., and Rolls, A. (2017). High-dimensional, single-cell characterization of the brain's immune compartment. *Nat. Neurosci.* **20**, 1300–1309.
- Latini, A., Novelli, L., Ceccarelli, F., Barbati, C., Perricone, C., De Benedittis, G., Conti, F., Novelli, G., Ciccacci, C., and Borgiani, P. (2021). mRNA expression analysis confirms CD44 splicing impairment in systemic lupus erythematosus patients. *Lupus* **30**, 1086–1093.
- Lindner, M., Klotz, L., and Wiendl, H. (2018). Mechanisms underlying lesion development and lesion distribution in CNS autoimmunity. *J. Neurochem.* **146**, 122–132.
- Loh, T.J., Moon, H., Cho, S., Jang, H., Liu, Y.C., Tai, H., Jung, D.-W., Williams, D.R., Kim, H.-R., Shin, M.-G., et al. (2015). CD44 alternative splicing and hnRNP A1 expression are associated with the metastasis of breast cancer. *Oncol. Rep.* **34**, 1231–1238.
- Luz, A., Fainstein, N., Einstein, O., and Ben-Hur, T. (2015). The role of CNS TLR2 activation in mediating innate versus adaptive neuroinflammation. *Exp. Neurol.* **273**, 234–242.
- Martino, M.M., Maruyama, K., Kuhn, G.A., Satoh, T., Takeuchi, O., Müller, R., and Akira, S. (2016). Inhibition of IL-1R1/MyD88 signalling promotes mesenchymal stem cell-driven tissue regeneration. *Nat. Commun.* **7**, 11051.
- McDonald, B., and Kubes, P. (2015). Interactions between CD44 and hyaluronan in leukocyte trafficking. *Front.Immunol.* **6**, 68.
- Midgley, A.C., Oltean, S., Hascall, V., Woods, E.L., Steadman, R., Phillips, A.O., and Meran, S. (2017). Nuclear hyaluronidase 2 drives alternative splicing of CD44 pre-mRNA to determine profibrotic or antifibrotic cell phenotype. *Sci. Signal.* **10**, eaao1822.
- Miller, S.D., Karpus, W.J., and Davidson, T.S. (2010). Experimental autoimmune encephalomyelitis in the mouse. *Current Protocols in Immunology* **88**, 15.1.1–15.1.20.
- Miyachi, E., Kim, S.-W., Suda, W., Kawasumi, M., Onawa, S., Taguchi-Atarashi, N., Morita, H., Taylor, T.D., Hattori, M., and Ohno, H. (2020). Gut microorganisms act together to exacerbate inflammation in spinal cords. *Nature* **585**, 102–106.
- Mousavi, A. (2020). CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy. *Immunol.Lett.* **217**, 91–115.
- Nicolò, C., Di Sante, G., Orsini, M., Rolla, S., Columba-Cabezas, S., Romano Spica, V., Ricciardi, G., Chan, B.M.C., and Ria, F. (2006). *Mycobacterium tuberculosis* in the adjuvant modulates the balance of Th immune response to self-antigen of the CNS without influencing a “core” repertoire of specific T cells. *Int. Immunol.* **18**, 363–374.
- Nicolò, C., Sali, M., Di Sante, G., Geloso, M.C., Signori, E., Penitente, R., Uniyal, S., Rinaldi, M., Ingrosso, L., Fazio, V.M., et al. (2010). *Mycobacterium smegmatis* expressing a chimeric protein MPT64-proteolipid protein (PLP) 139–151 reorganizes the PLP-specific T cell repertoire favoring a CD8-mediated response and induces a relapsing experimental autoimmune encephalomyelitis. *J. Immunol.* **184**, 222–235.
- Nicolò, C., Di Sante, G., Procoli, A., Migliara, G., Piermattei, A., Valentini, M., Delogu, G., Cittadini, A., Constantin, G., and Ria, F. (2013). M tuberculosis in the adjuvant modulates time of appearance of CNS-specific effector T cells in the spleen through a polymorphic site of TLR2. *PLoS ONE* **8**, e55819.
- Novelli, L., Barbati, C., Ceccarelli, F., Perricone, C., Spinelli, F.R., Alessandri, C., Valesini, G., Perricone, R., and Conti, F. (2019). CD44v3 and CD44v6 isoforms on T cells are able to discriminate different disease activity degrees and phenotypes in systemic lupus erythematosus patients. *Lupus* **28**, 621–628.
- Oukka, M., and Bettelli, E. (2018). Regulation of lymphocyte trafficking in central nervous system autoimmunity. *Curr.Opin.Immunol.* **55**, 38–43.
- Paz, I., Akerman, M., Dror, I., Kosti, I., and Mandel-Gutfreund, Y. (2010). SFmap: a web server for motif analysis and prediction of splicing factor binding sites. *Nucleic Acids Res.* **38**, W281–W285.
- Penitente, R., Nicolò, C., Van den Elzen, P., Di Sante, G., Agrati, C., Aloisi, F., Sercarz, E.E., and Ria, F. (2008). Administration of PLP<sub>139–151</sub> primes T cells distinct from those spontaneously responsive *in vitro* to this antigen. *J. Immunol.* **180**, 6611–6622.
- Perry, V.H., Cunningham, C., and Holmes, C. (2007). Systemic infections and inflammation affect chronic neurodegeneration. *Nat. Rev. Immunol.* **7**, 161–167.
- Piermattei, A., Migliara, G., Di Sante, G., Foti, M., Hayrabadyan, S.B., Papagna, A., Geloso, M.C., Corbi, M., Valentini, M., Sgambato, A., et al. (2016). Toll-like receptor 2 mediates *in vivo* pro- and anti-inflammatory effects of *Mycobacterium tuberculosis* and modulates autoimmune encephalomyelitis. *Front.Immunol.* **7**, 191.
- Pirolli, D., Sciandra, F., Bozzi, M., Giardina, B., Brancaccio, A., and De Rosa, M.C. (2014). Insights from molecular dynamics simulations: structural basis for the V567D mutation-induced instability of zebrafish alpha-dystroglycan and comparison with the murine model. *PLoS ONE* **9**, e103866.
- Ponta, H., Sherman, L., and Herrlich, P.A. (2003). CD44: from adhesion molecules to signalling regulators. *Nat. Rev. Mol. Cell Biol.* **4**, 33–45.
- Righino, B., Galissou, F., Pirolli, D., Vitale, S., Réty, S., Gouet, P., and De Rosa, M.C. (2018). Structural model of the full-length Ser/Thr protein kinase StkP from *S. pneumoniae* and its recognition of peptidoglycan fragments. *J. Biomol.Struct.Dyn.* **36**, 3666–3679.
- Roy, A., Kucukural, A., and Zhang, Y. (2010). I-TASSER: a unified platform for automated protein structure and function prediction. *Nat. Protoc.* **5**, 725–738.
- Sandor, A.M., Jacobelli, J., and Friedman, R.S. (2019). Immune cell trafficking to the islets during type 1 diabetes. *Clin. Exp. Immunol.* **198**, 314–325.
- Sen, S., Jumaa, H., and Webster, N.J.G. (2013). Splicing factor SRSF3 is crucial for hepatocyte differentiation and metabolic function. *Nat. Commun.* **4**, 1336.
- Shivakumar, D., Williams, J., Wu, Y., Damm, W., Shelley, J., and Sherman, W. (2010). Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. *J. Chem. Theor. Comput.* **6**, 1509–1519.
- Strazza, M., Azulay-Alfaguter, I., Silverman, G.J., and Mor, A. (2015). T cell chemokine receptor patterns as pathogenic signatures in autoimmunity. *Discov. Med.* **19**, 117–125.
- Sugano, E., Isago, H., Wang, Z., Murayama, N., Tamai, M., and Tomita, H. (2011). Immune responses to adeno-associated virus type 2 encoding channelrhodopsin-2 in a genetically blind rat model for gene therapy. *Gene Ther.* **18**, 266–274.
- Thompson, A.J., Banwell, B.L., Barkhof, F., Carroll, W.M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M.S., et al. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol.* **17**, 162–173.
- Thorsen, K., Mansilla, F., Schepeler, T., Øster, B., Rasmussen, M.H., Dyrskjöt, L., Karni, R., Akerman, M., Krainer, A.R., Laurberg, S., et al. (2011). Alternative splicing of SLC39A14 in colorectal cancer is regulated by the Wnt pathway. *Mol. Cell Proteomics* **10**, M110.002998.
- Tijink, B.M., Buter, J., de Bree, R., Giaccone, G., Lang, M.S., Staab, A., Leemans, C.R., and van Dongen, G.A.M.S. (2006). A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. *Clin.Cancer Res.* **12**, 6064–6072.
- Todaro, M., Gaggianesi, M., Catalano, V., Benfante, A., Iovino, F., Biffoni, M., Apuzzo, T., Sperduti, I., Volpe, S., Cocorullo, G., et al. (2014). CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. *Cell Stem Cell* **14**, 342–356.
- Tripathi, V., and Zhang, Y.E. (2017). Redirecting RNA splicing by SMAD3 turns TGF- $\beta$  into a tumor promoter. *Mol. Cell Oncol.* **4**, e1265699.
- Vallée, A., Vallée, J.-N., Guillevin, R., and Lecarpentier, Y. (2018). Interactions between the canonical WNT/beta-catenin pathway and PPAR gamma on neuroinflammation, demyelination, and remyelination in multiple sclerosis. *Cell. Mol. Neurobiol.* **38**, 783–795.
- Vestweber, D. (2015). How leukocytes cross the vascular endothelium. *Nat. Rev. Immunol.* **15**, 692–704.

Wang, X., Du, Z., Liu, X., Song, Y., Zhang, G., Wang, Z., Wang, Q., Gao, Z., Wang, Y., and Wang, W. (2017). Expression of CD44 standard form and variant isoforms in human bone marrow stromal cells. *Saudi Pharm. J.* 25, 488–491.

Weidle, U.H., Maisel, D., Klostermann, S., Weiss, E.H., and Schmitt, M. (2011).

Differential splicing generates new transmembrane receptor and extracellular matrix-related targets for antibody-based therapy of cancer. *Cancer Genom. Proteomics* 8, 211–226.

Yang, C., Liang, H., Zhao, H., and Jiang, X. (2012). CD44 variant isoforms are specifically

expressed on peripheral blood lymphocytes from asthmatic patients. *Exp. Ther. Med.* 4, 79–83.

Zhang, Y., Qian, J., Gu, C., and Yang, Y. (2021). Alternative splicing and cancer: a systematic review. *Sig. Transduct. Target. Ther.* 6, 78.

## STAR★METHODS

### KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
<b>Antibodies</b>		
CD49d ( $\alpha 4$ -integrin/VLA4)	BD Biosciences	Cat# 564397; RRID:AB_2738789
CD11a (LFA-1)	BD Biosciences	Cat# 746310; RRID:AB_2743634
CD62L (L-Selectin)	BD Biosciences	Cat# 746726; RRID:AB_2743990
CD44 antibody	BD Biosciences	Cat# 746710; RRID:AB_2743977
CD4 MicroBeads, human	Miltenyi Biotec	Cat#130-045-101;RRID:AB_2889919
TCR $\nu\beta 10$ PE-conjugated	BD Biosciences	Cat# 553285; RRID:AB_394757
APC-conjugated IgG	BD Biosciences	Cat# 554014; RRID:AB_395209
$\beta$ -Catenin Antibody	Cell Signaling Technology	Cat# 9562; RRID:AB_331149
Phospho- $\beta$ -Catenin (Ser675)	Cell Signaling Technology	Cat# 4176; RRID:AB_1903923
$\beta$ -Actin	Cell Signaling Technology	Cat# 12620; RRID:AB_2797972
Anti-Rabbit secondary antibody	ThermoFisher Scientific	Cat# 31466; RRID:AB_10960844
<b>Biological samples</b>		
Cerebrospinal fluid (CSF) from MS patients	Università Cattolica del Sacro Cuore	N/A
Whole blood samples from MS patients and healthy donors	Università Cattolica del Sacro Cuore	N/A
<b>Chemicals, peptides, and recombinant proteins</b>		
Pam2CSK4	InvivoGen	tlrl-pm2s-1
Pam3CSK4	InvivoGen	tlrl-pms
LPS-B5 (Ultrapur)	InvivoGen	tlrl-pb5lps
ODN 1585 (CpG)	InvivoGen	tlrl-1585
<b>Critical commercial assays</b>		
Cell Trace™ CFSE Cell Proliferation Kit	Invitrogen	C34554
CD4 <sup>+</sup> CD62L <sup>+</sup> T Cell Isolation Kit mouse	Miltenyi Biotec	130-106-643
T Cell Activation/Expansion Kit mouse	Miltenyi Biotec	130-093-627
T Cell Activation/Expansion Kit human	Miltenyi Biotec	130-091-441
Bordetella Pertussis toxin	Sigma-Aldrich	P7208
Freund's Adjuvant, Complete	Sigma-Aldrich	F5881
PLP (139-151)	Bio-technie	2567/1
Matrigel® Basement Membrane Matrix	Corning	356234
Collagen, Type I	Sigma-Aldrich	C3867
Osteopontin	Sigma-Aldrich	O2260
Cell Counting Kit (CCK)	Sigma-Aldrich	03285
WT Expression Kit	Thermo Fisher Scientific	4411974
GeneChip® WT Terminal Labeling kit	Thermo Fisher Scientific	901524
SYBR® Green Supermix	Biorad	170-8882:
<b>Experimental models: Cell lines</b>		
Primary Human CD4 <sup>+</sup> T cells cultures	This study	N/A
Primary Murine splenocyte cultures	This study	N/A
<b>Experimental models: Organisms/strains</b>		
SJL/J	Charles River Laboratories	RRID:IMSR_JAX:000686
C57BL/6NCrl	Charles River Laboratories	RRID:IMSR_CRL:027

(Continued on next page)

**Continued**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
C57BL/6 <sup>TLR2-/-</sup>	Jackson Laboratories	RRID:IMSR_JAX:004650
C57BL/6 <sup>MYD88-/-</sup>	Jackson Laboratories	RRID:IMSR_JAX:009088
SJL/J <sup>vb10+</sup>	Polygene Transgenetics	N/A
<b>Oligonucleotides</b>		
All human primers used are listed in <a href="#">Table S1</a>	This paper	N/A
All mouse primers used are listed in <a href="#">Table S2</a>	This paper	N/A
<b>Software and algorithms</b>		
Prism 9	GraphPad	<a href="https://www.graphpad.com">https://www.graphpad.com</a> RRID:SCR_002798
Kaluza Software	Beckman Coulter	<a href="https://www.beckman.it/flow-cytometry/software/kaluza">https://www.beckman.it/flow-cytometry/software/kaluza</a> RRID:SCR_016182
TAC Software	Thermo Fisher Scientific	<a href="https://www.thermofisher.com/it/en/home/global/forms/life-science/download-tac-software.html">https://www.thermofisher.com/it/en/home/global/forms/life-science/download-tac-software.html</a> RRID:SCR_016519
I-TASSER	University of Michigan	<a href="http://www.zhanggroup.org/I-TASSER/">www.zhanggroup.org/I-TASSER/</a> RRID:SCR_014627
Desmond	D. E. Shaw Research	<a href="https://www.deshawresearch.com/resources_desmond.html">https://www.deshawresearch.com/resources_desmond.html</a> RRID:SCR_014575
Alliance Q9 Advanced	UVITEC Cambridge	<a href="https://www.uvitec.co.uk/alliance-q9-advanced/N/A">https://www.uvitec.co.uk/alliance-q9-advanced/N/A</a>
SFmap	<a href="#">Paz et al. (2010)</a>	<a href="http://sfmap.technion.ac.il/N/A">http://sfmap.technion.ac.il/N/A</a>

**RESOURCE AVAILABILITY****Lead contact**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Gabriele Di Sante ([gabriele.disante@unipg.it](mailto:gabriele.disante@unipg.it))

**Materials availability**

This study did not generate new unique reagents.

**Data and code availability**

Data reported in this paper will be shared by the lead contact upon request.

This paper does not report original code.

All additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

**EXPERIMENTAL MODEL AND SUBJECT DETAILS****Human CSF and blood collection**

Thirty-four RR-MS patients were recruited at MS Centers at the "Fondazione Policlinico Universitario A. Gemelli" - Catholic University of the Sacred Heart of Rome (demographic and clinical characteristics are summarized in [Table 2](#)). All patients were affected by Relapsing-Remitting (RR)MS defined according to revised McDonald's criteria ([Thompson et al., 2018](#)). At the time of enrollment patients were free from immunomodulatory (never treated with disease-modifying drugs or therapy stopped by more than 6 months earlier) or immunosuppressive treatment (no immunosuppressive treatment for at least 2 years). From the whole cohort, we collected cerebrospinal fluid (CSF) samples that we analyzed for CD44 variants as described above.

## Mice

For all experiments, only 6–8 weeks old female mice were used. The breeding, the backcrossing and the maintenance of mice were performed at the animal facility of Università Cattolica del Sacro Cuore, CenRis. All experimental work has been conducted in accordance with relevant national legislation on the use of animals for research, referring to the Code of Practice for the Housing and Care of Animals Used in Scientific Procedures and the protocol was approved by the Ethics Committee of animal welfare organization (OPBA) of the “Università Cattolica del Sacro Cuore” of Rome and by the Italian Ministry of Health (authorization number 321/2017-PR, protocol number 1F295.34/04-11-2016, date of approval April, 12th 2017).

## METHODS DETAILS

### Animal procedures

The RR-EAE have been induced by immunizing SJL/J mice subcutaneously (s.c.) at the base of the tail with an emulsion of myelin antigen PLP<sub>139-151</sub> (75 µg/20g, purchased from Primmbiotech, Italy) and 4X-concentrated complete Freund’s adjuvant (CFA, 200µg of *Mycobacterium Tuberculosis* wall for each mouse of about 20g, purchased from Sigma-Aldrich, Merck, Germany). To help breaking the BBB, a double dosage of *Bordetella Pertussis* toxin (BDT, total 300 ng/20g mouse, purchased from Sigma-Aldrich, Merck, Germany) have been administered at day 0 and 3. After treatment, mice of all groups have been daily monitored for body weight and the development of clinical signs and symptoms (CSS) following the score scale described in (Baker and Amor, 2012; Camponeschi et al., 2021; Miller et al., 2010; Nicolò et al., 2006). According to this score scale, the EAE scale comprises a range of value between 0 (no clinical symptoms observed) and 3 (mouse paralysis). After perfusion with PBS, from each EAE affected mouse different samples were collected: spleen, blood and CNS of which one hemisphere and the spinal cord have been employed for morphological analyses and the other for molecular analyses. Control mice were sacrificed accordingly. The cellular studies were performed after the collection of splenocytes of different mouse strains: SJL/J<sup>wt</sup>, C57BL/6<sup>wt</sup>, C57BL/6<sup>TLR2<sup>-/-</sup></sup>, F1(SJL/J<sup>wt</sup> × C57BL/6<sup>TLR2<sup>-/-</sup></sup>), F1(SJL/J<sup>wt</sup> × C57BL/6<sup>wt</sup>), C57BL/6<sup>MYD88<sup>-/-</sup></sup>, SJL/J<sup>v<sup>b</sup>10<sup>+</sup></sup>. The TLR2-KO mice was purchased from Charles River (Nicolò et al., 2013) while the insertion of the  $\nu\beta 10$ -transgene was generated by Polygene Transgenetics (Rümlang, Switzerland) in C57BL/6 mice and then transferred (after more than 10 generation) to SJL/J strain (Piermattei et al., 2016). For flow cytometric analysis the strains of mice listed above were immunized s.c. with PLP<sub>139-151</sub> (50 µg/20g) emulsified alternatively with 1X or 4X CFA (50 or 200 µg/20g). Draining popliteal lymph nodes (LN) were collected 8 days after the immunizations.

### Cell culture

We performed an *in vitro* experiment, on naïve splenocytes collected from 8-10 weeks old female SJL/J<sup>wt</sup>, C57BL/6<sup>wt</sup> and F1 SJL/J hybridized C57BL/6<sup>wt</sup> or C57BL/6<sup>TLR2<sup>-/-</sup></sup>. After the enrichment of T helper cells using a negative magnetic separation cocktail purchased from Miltenyi Biotec, we subdivided these cells using CD62L magnetic antibody provided in the same kit; after checking the purity of the sorted subpopulation was higher than 95%, we measured the ability of CD4<sup>+</sup>/CD62L<sup>low</sup> T cells to interact with extracellular matrix *in vitro* using 96 transwells with 5 µm pores and Matrigel in a standard assay or polymerized with osteopontin (100 ng/µL) or type I collagen (4 mg/mL), upon different stimulations in the presence or absence of synthetic ligands for TLR2, such as PAM2/CSK4 (100 ng/mL), PAM3/CSK4 (100 ng/mL) or PPD (25 µg/mL), for TLR4, such as LPS (20 µg/mL), for TLR9, such as CpG (2 ng/mL) and of T cell activation microparticles for mouse (with  $\alpha$ CD3/ $\alpha$ CD28) and for human ( $\alpha$ CD3/ $\alpha$ CD28/ $\alpha$ CD2). The assay was performed also in the presence of blocking, anti-pan CD44 mAb (clone Rat IgG2a, clone MJ-64), to assess the contribution of this molecule to modification of trafficking. T cells were cultured in this invasion test for 6, 12 and 24 h and at each time point have been harvested from the upper and lower chamber and recovered from the Matrigel and counted using flow cytometer (Cytoflex) and software (Kaluza 2.1.1.) and analyzed with a proliferation assay (CCK8) evaluating absorbance with microplates reader (Tecan, Switzerland).

In addition, we enriched CD4<sup>+</sup>CD62L<sup>low</sup> T cells from the spleens of naïve SJL/J<sup>wt</sup> (n = 3) and C57BL/6<sup>wt</sup> (n = 4) mice and cultured them in the absence of any stimulus, in the absence or presence of TLR-9,-4,-2/6 or -2/1 ligands (respectively CpG, LPS, PAM2/CSK4 or PAM3/CSK4, alone or combined with microparticles conjugated with  $\alpha$ CD3/ $\alpha$ CD28 (mouse T cell activation kit from Miltenyi Biotec). After 16 h, cells were

collected, and the mRNA was extracted. RT-qPCR was performed as described below for CD44 splicing variants, splicing factors and housekeeping genes.

For human cell cultures we enriched CD4<sup>+</sup> T cells (Miltenyi Biotec) from PBMC (separated with gradient of Lympholite, Cedarlane) of healthy donors (n = 3) and MS patients (n = 7) and cultured in the absence of any stimulus, in the absence or presence of TLR-9, -4, -2/6 or -2/1 ligands (respectively CpG, LPS, PAM2/CSK4 or PAM3/CSK4, alone or combined with microparticles conjugated with human T cell activation kit. After 24 h, cells were harvested, and the mRNA was extracted. RT-qPCR was performed as described below for CD44 splicing variants and housekeeping genes.

### Flow cytometry

We examined the expression on the T cell surface of 4 markers known to play a relevant role in the interaction between leukocytes and endothelia, namely  $\alpha$ 4-integrin/VLA4 (CD49d), LFA1 (CD11a), L-selectin (CD62L), CD44, used at a concentration of 5  $\mu$ g/10<sup>6</sup> cells. To examine the level of expression of these proteins only on activated Ag-specific T cells by flow cytometry, we took advantage of a mouse SJL/J strain transgenic for the  $\beta$ -chain of a public TCR specific for PLP<sub>139-151</sub> in the same strain (Nicolò et al., 2006, 2010). This strain was obtained by back crossing the C57Bl/6<sup>v $\beta$ 10+</sup> transgenic mouse described in three for more than 10 generations onto the SJL/J strain (SJL/J<sup>v $\beta$ 10+</sup>). Reflecting the general characteristics of the pathogenic PLP<sub>139-151</sub>-specific repertoire (Penitente et al., 2008). T cells expressing this transgenic  $\beta$ -chain and the appropriate  $\beta$ -chain are not spontaneously activated *in vivo* but become activated by PLP<sub>139-151</sub> upon immunization with the peptide.

SJL/J<sup>v $\beta$ 10+</sup> mice were immunized with PLP<sub>139-151</sub> in IFA containing 200 (fast mobilizer) or 50 (slow mobilizer)  $\mu$ g/20g of heat-killed *Mtb*, and F1(SJL/J<sup>v $\beta$ 10+</sup> $\times$ B6<sup>wt</sup>) (fast mobilizer) and F1(SJL/J<sup>v $\beta$ 10+</sup> $\times$ B6<sup>tlr2-</sup>) (slow mobilizer) were challenged with the same amount of PLP<sub>139-151</sub> in IFA containing 50  $\mu$ g/20g of heat-killed *Mtb*. Cells from popliteal draining lymph nodes were recovered at day 8 post-immunization, labeled with 1.5  $\mu$ M of carboxy-fluorescein succinimidyl ester (CFSE, Invitrogen, Thermo Fisher Scientific) and stimulated *in vitro* with PLP<sub>139-151</sub>. Three days later, cells were recovered stained for TCR v $\beta$ 10 PE-conjugated (BD Pharmingen, Thermo Fisher Scientific), CD49d, CD11a, CD62L and CD44 above described and combined with an APC-conjugated Goat anti-rat IgG (BD Pharmingen, Thermo Fisher Scientific), and the expression of these markers was compared on v $\beta$ 10<sup>high</sup>/CFSE<sup>low</sup> cells, i.e. T cells that had proliferated in response to PLP<sub>139-151</sub>. Gating strategy and results are reported in Figure 1.

### RT-qPCR assays

CNS mouse samples were collected as described above, while human cerebrospinal fluids (CSF) were centrifuged at 1,200 rpm for 10 min and pellet were stored in TRIzol™ reagent at -80°C. Total RNA was isolated from mice and human samples with Direct-zol Rna Micro-Prep (Zymo Research). RNA concentration was evaluated by spectrophotometric reading at 280 and 260 nm. Total RNA was used for first strand cDNA synthesis with cDNA Sensifast kit (Bioline). The quantification of gene expression was obtained from Biorad instruments and products (iQ5 Multicolor Real-Time PCR Detection System, SYBR Green Master Mix and semiskirted 96 well plates) according to the manufacturer's recommendations. Primers were deduced from literature both for human (Sugano et al., 2011; Wang et al., 2017) (Table S1) and murine (Bader et al., 2003; Cao and Malon, 2018; Giampietro et al., 2015; Piermattei et al., 2016; Sen et al., 2013) (Table S2) sequences genes. Each gene target quantification reaction was performed separately with the respective primer sets. Conditions were set as follows: 50°C for 2 min, followed by 95°C for 10 min, forty cycles at 95°C for 15 s, followed by 60°C for 1 min. The melt standard curve was at 95°C for 15 s, followed by 60°C for 1 min, 95°C for 15 s, and finally, 60°C for 15 s. Gene expression results were analyzed using Biorad software. For the expression of murine CD44 variants (standard, v1-v10, v8-v10 and v9-v10) ready-to-use-assays have been purchased (Figure S6) following Applied Biosystems protocol of Taqman Universal Master Mix II with UNG. Relative mRNA expression levels were calculated by normalizing examined genes against  $\beta$ -actin using the 2<sup>- $\Delta$ Ct</sup> method.

### Model building and simulation of molecular dynamics

The molecular models of the CD44 isoforms were built using I-TASSER, a metaserver that automatically employs ten threading algorithms in combination with ab initio modeling to generate the tertiary structure of a protein as well as replica-exchange Monte Carlo dynamics (REMD) simulations for the



atomic-level refinement (Pirolli et al., 2014; Roy et al., 2010). The quality of the models generated by I-TASSER are evaluated accordingly to the C-score value, provided by the same program. The C-score was calculated based on the significance of the threading alignments and the convergence of the I-TASSER simulations. C-scores typically range from  $-5$  to  $1$ , with higher scores reflecting a model of better quality. To take into account protein flexibility and solvent effects, the behavior of the model structures was studied in a dynamic context by molecular dynamics (MD) simulations and the solvent accessible surface area (SASA) was monitored (Righino et al., 2018). Average SASA values from MD simulations may therefore estimate the surface area that is available for contact with solvents and other molecules. Indeed, surface properties play a key role in determining the interactions between the protein and various other molecules and solvent and may provide important information on functional properties.

Molecular dynamics (MD) simulations of the model structures were executed using Desmond, version Build 13 (D. E. Shaw Research, New York) as implemented in the Schrodinger Suite 2020-1 (Schrödinger Inc.) employing the OPLS2005 force field (Shivakumar et al., 2010). The systems for the simulations were built with the “System Builder” tool of the Maestro suite (Schrödinger Inc.), drawing an orthorhombic box around each CD44 isoform with a distance buffer of  $10 \text{ \AA}$  between the protein and the side of the box, and filling it with SPC water molecules. A  $0.15 \text{ M}$  NaCl salt concentration was added, and the system was neutralized by additional  $\text{Na}^+$  ions. The Particle-Mesh Ewald method was used to calculate long-range electrostatic interactions and the SHAKE algorithm was used to constrain the bonds. van der Waals and short-range electrostatic interactions were smoothly truncated at  $9.0 \text{ \AA}$ . The systems were equilibrated with the default protocol provided in Desmond. Subsequently,  $200 \text{ ns}$  MD simulations were carried for each system and the SASA calculated from the trajectories was analyzed using VMD (Humphrey et al., 1996).

### Gene expression microarray

Total RNA ( $100 \text{ ng}$ /each sample or each control) was processed using the Ambion WT Expression kit;  $5.5 \text{ \mu g}$  of ss-cDNA were fragmented with GeneChip WT Terminal Labeling kit and labeled with biotin using terminal deoxynucleotidyl transferase, before hybridization ( $50 \text{ pM}$  control oligonucleotide B2;  $15$ ,  $5$ ,  $25$ , and  $100 \text{ p.m.}$ , respectively, of BioB, BioC, BioD, and cre hybridization controls;  $1 \times$  hybridization mix;  $10\%$  Dimethylsulfoxide; nuclease-free water): this mixture was heated to  $99^\circ\text{C}$  for  $5 \text{ min}$  and to  $45^\circ\text{C}$  for another  $5 \text{ min}$ . Then, it was injected into Affymetrix Mouse Exon 1.0 ST microarray chips, and the hybridization was performed under rotation at  $45^\circ\text{C} \pm 16 \text{ h}$ . The GeneChip Mouse Exon 1.0 ST Array is a single array with over  $4.5$  million unique  $25$ -mer oligonucleotide features constituting approximately  $1.2$  million probe sets. For the gene-level analysis, the chip contains about  $23,339$  probe sets (Piermattei et al., 2016).

### Western blot

Splenocytes were collected from naïve female SJL/J mice.  $\text{CD4}^+\text{CD62L}^{\text{low}}$  T cells were enriched using  $\text{CD4}^+\text{CD62L}^+$  T cell Isolation Kit II. Cells were plated and stimulated *in vitro* with PAM2/CSK4, PAM3/CSK4 and  $\alpha\text{CD3}/\alpha\text{CD28}$  T cell activation microparticles for mouse. After  $1$  and  $6 \text{ h}$ , cells were harvested, washed with PBS  $1 \times$ . Cell pellets were stored at  $-80^\circ\text{C}$ . Control and treated cells were lysate in ice-cold RIPA Lysis and Extraction Buffer (Thermo Fisher Scientific) completed with Halt Protease Inhibitor Cocktail and Halt Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific). The protein lysates ( $30 \text{ \mu g}$ ) were separated on Bolt  $4$ – $12\%$  SDS–polyacrilamide gel (Thermo Fisher Scientific) and electroblotted onto PolyVinylidene-DiFluoride membrane (PVDF, Amersham, Merck, Germany). Nonspecific binding sites were blocked by SuperBlock<sup>TM</sup> (TBS) Blocking Buffer (Thermo Fisher Scientific) for  $1 \text{ h}$  at room temperature. Membranes were then incubated overnight at  $4^\circ\text{C}$  with the following primary antibodies, diluted in TBS-T and  $5\%$  non-fat dry milk or  $5\%$  BSA (Sigma-Aldrich, Merck):  $\beta$ -catenin  $1:1000$ , P- $\beta$ -catenin  $1:1000$ ,  $\beta$ -actin  $1:1000$ . The day after, membranes were incubated with the secondary, HRP-conjugated anti-rabbit antibody (Thermo Fisher Scientific) for  $2 \text{ h}$ . Immunoreactive bands were visualized by Pierce<sup>TM</sup> ECL Western Blotting Substrate (Thermo Fisher Scientific) according to manufacturer’s instructions. The densitometry analysis was determined and normalized to B-actin using Alliance Q9 Advanced UVITEC software.

### QUANTIFICATION AND STATISTICAL ANALYSIS

Student's *t*-test, one-way ANOVA or two-way ANOVA were performed to examine the effects and possible interaction of independent variables (GraphPad, Prism 9.3 software). When appropriate, post hoc comparisons were made using Tukey's HSD, with a significance level of  $p < 0.05$ . For statistical analysis of qPCR data, the unpaired *t*-test was used to compare  $\Delta\text{Ct}$  values across the replicates, setting the *p* value cut-off at 0.05. A gene-level analysis was performed by TAC software: a total of 23,339 genes were tested to compare their expression between three F1 (SJL/*J*<sup>wt</sup> × C57Bl/6<sup>Tlr2-</sup>) samples and three F1 (SJL/*J*<sup>wt</sup> × C57Bl/6<sup>wt</sup>) samples. The ANOVA was used for the detection of differentially expressed genes (DEGs). Only the probe sets whose fold changes were higher than or equal to 1.5 and *p* value of 0.05 were selected as modulated (Piermattei et al., 2016).